[
  {
    "slug": "17a-methyl-1-testosterone",
    "title": "17a-Methyl-1-testosterone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "17a-Methyl-1-testosterone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "17a-Methyl-1-testosterone belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "17a-Methyl-1-testosterone requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for 17a-Methyl-1-testosterone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most 17a-Methyl-1-testosterone users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact 17a-Methyl-1-testosterone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "17a-Methyl-1-testosterone may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is 17a-Methyl-1-testosterone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "17a-Methyl-1-testosterone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=17a-Methyl-1-testosterone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "17a-Methyl-1-testosterone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=17a-Methyl-1-testosterone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "17a-Methyl-1-testosterone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "17a-Methyl-1-testosterone",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "17a-Methyl-1-testosterone is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "17a-Methyl-1-testosterone should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact 17a-Methyl-1-testosterone timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for 17a-Methyl-1-testosterone often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "5-amino-1mq",
    "title": "5-amino-1mq",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "5-amino-1mq guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "5-amino-1mq belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "5-amino-1mq should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for 5-amino-1mq and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "5-amino-1mq is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log 5-amino-1mq timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "5-amino-1mq may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for 5-amino-1mq versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "5-amino-1mq: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=5-amino-1mq",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "5-amino-1mq: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=5-amino-1mq",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "5-amino-1mq: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "5-amino-1mq",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "5-amino-1mq is often approached as investigational support with variable evidence depth and variable product quality.",
      "5-amino-1mq is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "5-amino-1mq should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log 5-amino-1mq timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for 5-amino-1mq often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ace-031",
    "title": "ACE-031",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ACE-031 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ACE-031 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "ACE-031 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ACE-031 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "ACE-031 is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log ACE-031 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "ACE-031 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for ACE-031 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ACE-031: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ACE-031",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ACE-031: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ACE-031",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ACE-031: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ACE-031",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "ACE-031 is often approached as investigational support with variable evidence depth and variable product quality.",
      "ACE-031 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "ACE-031 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log ACE-031 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for ACE-031 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "adamax",
    "title": "Adamax",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Adamax guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Adamax should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Adamax, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Adamax and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Adamax is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Adamax timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Adamax may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Adamax versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Adamax: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Adamax",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Adamax: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Adamax",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Adamax: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Adamax",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Adamax is often approached as investigational support with variable evidence depth and variable product quality.",
      "Adamax is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Adamax should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Adamax timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Adamax often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "adipotide",
    "title": "Adipotide",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Adipotide guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Adipotide belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Adipotide should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Adipotide and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Adipotide is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Adipotide timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Adipotide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Adipotide versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Adipotide: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Adipotide",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Adipotide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Adipotide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Adipotide: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Adipotide",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Adipotide is often approached as investigational support with variable evidence depth and variable product quality.",
      "Adipotide is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Adipotide should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Adipotide timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Adipotide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ahk-cu",
    "title": "AHK-CU",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "AHK-CU guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "AHK-CU should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For AHK-CU, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for AHK-CU and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "AHK-CU is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log AHK-CU timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "AHK-CU may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for AHK-CU versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "AHK-CU: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=AHK-CU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "AHK-CU: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=AHK-CU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "AHK-CU: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "AHK-CU",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "AHK-CU is often approached as investigational support with variable evidence depth and variable product quality.",
      "AHK-CU is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "AHK-CU should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log AHK-CU timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for AHK-CU often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "aicar",
    "title": "Aicar",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Aicar guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Aicar should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Aicar, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Aicar and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Aicar is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Aicar timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Aicar may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Aicar versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Aicar: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Aicar",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Aicar: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Aicar",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Aicar: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Aicar",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Aicar is often approached as investigational support with variable evidence depth and variable product quality.",
      "Aicar is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Aicar should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Aicar timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Aicar often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "alprostadil",
    "title": "Alprostadil",
    "aliases": [],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Alprostadil guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Alprostadil is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Alprostadil protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Alprostadil and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Alprostadil is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Alprostadil timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Alprostadil versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Alprostadil: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Alprostadil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Alprostadil: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Alprostadil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Alprostadil: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Alprostadil",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach",
    "useCases": [
      "Alprostadil is often approached as investigational support with variable evidence depth and variable product quality.",
      "Alprostadil is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Alprostadil should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Alprostadil timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Alprostadil often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "anadrol",
    "title": "ANADROL",
    "aliases": [
      "ANADROL(Oxymetholone)"
    ],
    "category": "Oral Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "ANADROL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ANADROL tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "ANADROL decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ANADROL and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most ANADROL users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact ANADROL timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ANADROL appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ANADROL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ANADROL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ANADROL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ANADROL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ANADROL: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=ANADROL",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ANADROL",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound",
        "Supportive"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "ANADROL is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "ANADROL should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact ANADROL timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for ANADROL often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "anavar",
    "title": "ANAVAR",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ANAVAR guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For ANAVAR, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "ANAVAR should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ANAVAR and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most ANAVAR users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact ANAVAR timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "ANAVAR may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ANAVAR appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ANAVAR: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ANAVAR",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ANAVAR: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ANAVAR",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ANAVAR: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ANAVAR",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "ANAVAR is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "ANAVAR should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact ANAVAR timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for ANAVAR often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "andarine-s4",
    "title": "Andarine S4",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Andarine S4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Andarine S4, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Andarine S4 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Andarine S4 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Andarine S4 users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Andarine S4 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Andarine S4 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Andarine S4 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Andarine S4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Andarine%20S4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Andarine S4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Andarine%20S4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Andarine S4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Andarine S4",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Andarine S4 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Andarine S4 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Andarine S4 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Andarine S4 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "androxal-enclomiphene",
    "title": "Androxal(Enclomiphene)",
    "aliases": [
      "Androxal(Enclomiphene)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Androxal(Enclomiphene) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Androxal, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Androxal, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Androxal and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Androxal users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Androxal timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Androxal may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Androxal appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Androxal(Enclomiphene): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Androxal",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Androxal(Enclomiphene): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Androxal",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Androxal(Enclomiphene): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Androxal",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Androxal is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Androxal should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Androxal timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Androxal often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "aod-9604",
    "title": "AOD-9604",
    "aliases": [
      "HGH Fragment",
      "AOD9604"
    ],
    "category": "Fat Loss Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "AOD-9604 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "AOD-9604 conversations can drift into easy cut promises. The better approach is tight logging, stable baseline habits, and honest separation of signal from routine variability.",
    "dosingSection": {
      "overview": "For AOD-9604, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for AOD-9604 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "AOD-9604 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C4]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C4]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log AOD-9604 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "AOD-9604 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for AOD-9604 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "AOD-9604: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=AOD-9604",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "AOD-9604: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=AOD-9604",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "AOD-9604: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=AOD-9604",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "AOD-9604: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "AOD-9604",
    "subtitle": "AOD-9604 practical guide for conservative protocol interpretation.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "AOD-9604 is often approached as investigational support with variable evidence depth and variable product quality.",
      "AOD-9604 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "AOD-9604 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log AOD-9604 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for AOD-9604 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ara-290",
    "title": "ARA-290",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ARA-290 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ARA-290 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For ARA-290, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ARA-290 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "ARA-290 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log ARA-290 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "ARA-290 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for ARA-290 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ARA-290: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ARA-290",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ARA-290: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ARA-290",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ARA-290: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ARA-290",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "ARA-290 is often approached as investigational support with variable evidence depth and variable product quality.",
      "ARA-290 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "ARA-290 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log ARA-290 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for ARA-290 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "arimidex",
    "title": "ARIMIDEX",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "ARIMIDEX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ARIMIDEX tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With ARIMIDEX, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for ARIMIDEX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most ARIMIDEX users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact ARIMIDEX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ARIMIDEX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ARIMIDEX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ARIMIDEX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ARIMIDEX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ARIMIDEX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ARIMIDEX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "ARIMIDEX",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "ARIMIDEX is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "ARIMIDEX should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact ARIMIDEX timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for ARIMIDEX often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "aromasin-exemestane",
    "title": "Aromasin(Exemestane)",
    "aliases": [
      "Aromasin(Exemestane)"
    ],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Aromasin(Exemestane) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Aromasin is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Aromasin protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Aromasin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Aromasin users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Aromasin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Aromasin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Aromasin(Exemestane): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Aromasin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Aromasin(Exemestane): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Aromasin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Aromasin(Exemestane): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Aromasin",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Aromasin is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Aromasin should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Aromasin timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Aromasin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "b12",
    "title": "Vitamin B12",
    "aliases": [
      "Cyanocobalamin",
      "Methylcobalamin",
      "B12"
    ],
    "category": "Vitamin",
    "status": "nutrient",
    "statusLabel": "Nutrient Support",
    "metaDescription": "Vitamin B12 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "B12 support works best when form, timing, and symptom context are tracked together. This page helps you avoid generic energy felt better logs.",
    "dosingSection": {
      "overview": "For Vitamin B12, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Keep Vitamin B12 schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Vitamin B12, real-world dosing usually works best when baseline status is measured before aggressive correction. [C4]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C1]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C2]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C1]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C2]",
        "Re-check objective markers before extending high-intensity phases. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Vitamin B12 timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Vitamin B12, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vitamin B12: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Vitamin%20B12&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vitamin B12: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vitamin%20B12",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vitamin B12: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vitamin%20B12",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Vitamin B12: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vitamin%20B12+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Vitamin B12",
    "subtitle": "Vitamin B12 support guide with form and symptom-context notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Vitamin",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Vitamin B12 is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Nutrient Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Vitamin B12 should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Vitamin B12 timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Vitamin B12 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "bac-water",
    "title": "BAC Water",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "BAC Water guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BAC Water works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "BAC Water decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BAC Water and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "BAC Water is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log BAC Water timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BAC Water versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BAC Water: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BAC%20Water",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BAC Water: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BAC%20Water",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BAC Water: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=BAC%20Water",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BAC Water",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "support",
    "useCases": [
      "BAC Water is often approached as investigational support with variable evidence depth and variable product quality.",
      "BAC Water is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "BAC Water should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log BAC Water timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for BAC Water often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "bam15",
    "title": "BAM15",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BAM15 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For BAM15, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "BAM15 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BAM15 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most BAM15 users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact BAM15 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "BAM15 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BAM15 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BAM15: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BAM15",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BAM15: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BAM15",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BAM15: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BAM15",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "BAM15 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "BAM15 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact BAM15 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for BAM15 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "bc-boldenone-cyp",
    "title": "BC(Boldenone Cyp)",
    "aliases": [
      "BC(Boldenone Cyp)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BC(Boldenone Cyp) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BC should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "BC requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BC and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "BC outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact BC timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "BC may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BC appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BC(Boldenone Cyp): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BC",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BC(Boldenone Cyp): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BC(Boldenone Cyp): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BC",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "BC is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "BC should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact BC timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for BC often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "beinaglutide",
    "title": "Beinaglutide",
    "aliases": [
      "Benaglutide",
      "Beisu"
    ],
    "category": "GLP-1",
    "status": "regional-approval",
    "statusLabel": "Regional Approval",
    "metaDescription": "Beinaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Beinaglutide sits in a regional context, so good guidance means regulatory clarity first. This page frames what to verify before discussing protocol details.",
    "dosingSection": {
      "overview": "For Beinaglutide, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Beinaglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Beinaglutide protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C4]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C4]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C1]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Beinaglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Beinaglutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Beinaglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Beinaglutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Beinaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Beinaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Beinaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Beinaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Beinaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Beinaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Beinaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Beinaglutide",
    "subtitle": "Region-specific GLP-1 context with approval-boundary cautions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Regional Approval"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Beinaglutide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "regional_label",
      "plainLanguageStatus": "Regional Approval",
      "legalNotice": "Regional-label status varies by jurisdiction; this page is educational only and not treatment guidance."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Beinaglutide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Beinaglutide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Beinaglutide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "boron",
    "title": "Boron",
    "aliases": [
      "B"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Boron guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Boron tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Boron should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Boron schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Boron, real-world dosing usually works best when baseline status is measured before aggressive correction. [C3]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C1]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C2]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C1]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C2]",
        "Re-check objective markers before extending high-intensity phases. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Boron timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Boron, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Boron: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Boron-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Boron: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Boron",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Boron: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Boron+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Boron",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Boron is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Boron should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Boron timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Boron often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "botulinum-toxin",
    "title": "Botulinum toxin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Botulinum toxin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Botulinum toxin tracking improves fast once you define one clear objective and log against it every week. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Botulinum toxin, stable cadence is the foundation for any useful adjustment discussion. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Botulinum toxin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Botulinum toxin is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log Botulinum toxin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Botulinum toxin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Botulinum toxin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Botulinum%20toxin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Botulinum toxin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Botulinum%20toxin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Botulinum toxin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Botulinum toxin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach",
    "useCases": [
      "Botulinum toxin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Botulinum toxin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Botulinum toxin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Botulinum toxin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Botulinum toxin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "bpc-157",
    "title": "BPC-157",
    "aliases": [
      "Body Protection Compound 157"
    ],
    "category": "Healing Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC-157 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "BPC-157 notes are only useful when they tie symptoms to location, timeline, and load. Vague better or worse entries hide patterns. This guide pushes objective context over wishful interpretation.",
    "dosingSection": {
      "overview": "For BPC-157, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BPC-157 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "BPC-157 is usually paced conservatively in real-world use due to evidence and quality variability. [C4]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log BPC-157 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "BPC-157 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BPC-157 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC-157: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=BPC-157",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC-157: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=BPC-157",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC-157: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC-157",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "BPC-157: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "BPC-157",
    "subtitle": "Recovery-focused peptide logging with context-rich progress notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "BPC-157 is often approached as investigational support with variable evidence depth and variable product quality.",
      "BPC-157 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "BPC-157 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log BPC-157 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for BPC-157 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "bpc-500mcg-plus-tb500-500mcg-blend",
    "title": "BPC 500mcg+TB500 500mcg Blend",
    "aliases": [
      "BPC 500mcg+TB500 500mcg Blend"
    ],
    "category": "Compound Blend",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC 500mcg+TB500 500mcg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For BPC-157 + TB-500 Blend, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "BPC-157 + TB-500 Blend requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat BPC-157 + TB-500 Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "BPC-157 + TB-500 Blend is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Blend protocols are typically interpreted component-by-component so one reaction does not misclassify the entire stack. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "BPC-157 + TB-500 Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BPC-157 + TB-500 Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC 500mcg+TB500 500mcg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC%20500mcg%2BTB500%20500mcg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC 500mcg+TB500 500mcg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC%20500mcg%2BTB500%20500mcg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC 500mcg+TB500 500mcg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BPC-157 + TB-500 Blend",
    "subtitle": "BPC-157 + TB-500 blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "BPC-157",
        "amount": "500mcg"
      },
      {
        "name": "TB-500",
        "amount": "500mcg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "BPC-157 + TB-500 Blend is often approached as investigational support with variable evidence depth and variable product quality.",
      "BPC-157 + TB-500 Blend is a blend, so interpretation should stay component-aware instead of treating every response as one signal.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "BPC-157 + TB-500 Blend should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for BPC-157 + TB-500 Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "bpc157-10mg-plus-tb500-10mg-blend",
    "title": "BPC157 10mg+TB500 10mg Blend",
    "aliases": [
      "BPC157 10mg+TB500 10mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC157 10mg+TB500 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For BPC-157 + TB-500 Blend, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "BPC-157 + TB-500 Blend requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat BPC-157 + TB-500 Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "BPC-157 + TB-500 Blend is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Blend protocols are typically interpreted component-by-component so one reaction does not misclassify the entire stack. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "BPC-157 + TB-500 Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BPC-157 + TB-500 Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC157 10mg+TB500 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC157%2010mg%2BTB500%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC157 10mg+TB500 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC157%2010mg%2BTB500%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC157 10mg+TB500 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BPC-157 + TB-500 Blend",
    "subtitle": "BPC-157 + TB-500 blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "BPC-157",
        "amount": "10mg"
      },
      {
        "name": "TB-500",
        "amount": "10mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "BPC-157 + TB-500 Blend is often approached as investigational support with variable evidence depth and variable product quality.",
      "BPC-157 + TB-500 Blend is a blend, so interpretation should stay component-aware instead of treating every response as one signal.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "BPC-157 + TB-500 Blend should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for BPC-157 + TB-500 Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "bpc157-5mg-plus-tb500-5mg-blend",
    "title": "BPC157 5mg+TB500 5mg Blend",
    "aliases": [
      "BPC157 5mg+TB500 5mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC157 5mg+TB500 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BPC-157 + TB-500 Blend should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For BPC-157 + TB-500 Blend, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Treat BPC-157 + TB-500 Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "BPC-157 + TB-500 Blend is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Blend protocols are typically interpreted component-by-component so one reaction does not misclassify the entire stack. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "BPC-157 + TB-500 Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for BPC-157 + TB-500 Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC157 5mg+TB500 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC157%205mg%2BTB500%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC157 5mg+TB500 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC157%205mg%2BTB500%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC157 5mg+TB500 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BPC-157 + TB-500 Blend",
    "subtitle": "BPC-157 + TB-500 blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "BPC-157",
        "amount": "5mg"
      },
      {
        "name": "TB-500",
        "amount": "5mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "BPC-157 + TB-500 Blend is often approached as investigational support with variable evidence depth and variable product quality.",
      "BPC-157 + TB-500 Blend is a blend, so interpretation should stay component-aware instead of treating every response as one signal.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "BPC-157 + TB-500 Blend should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log BPC-157 + TB-500 Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for BPC-157 + TB-500 Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "bu-equipoise",
    "title": "BU(EQUIPOISE)",
    "aliases": [
      "BU(EQUIPOISE)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BU(EQUIPOISE) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BU should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "BU requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for BU and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "BU outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact BU timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "BU may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BU appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BU(EQUIPOISE): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BU(EQUIPOISE): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BU(EQUIPOISE): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "BU",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "BU is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "BU should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact BU timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for BU often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cabergoline",
    "title": "Cabergoline",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Cabergoline guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cabergoline is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With Cabergoline, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Cabergoline and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Cabergoline users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Cabergoline timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Cabergoline appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cabergoline: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cabergoline",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cabergoline: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cabergoline",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cabergoline: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Cabergoline",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Cabergoline is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Cabergoline should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Cabergoline timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Cabergoline often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cagrilintide",
    "title": "Cagrilintide",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Cagrilintide guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cagrilintide changes appetite patterns in ways that can be subtle at first. Better logs capture timing and meal context, not just total intake.",
    "dosingSection": {
      "overview": "For Cagrilintide, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Cagrilintide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Cagrilintide protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C1]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C1]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C2]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Cagrilintide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Cagrilintide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Cagrilintide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cagrilintide: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cagrilintide",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cagrilintide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cagrilintide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cagrilintide: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Cagrilintide",
    "subtitle": "Amylin-pathway peptide context with appetite-pattern emphasis.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Cagrilintide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Cagrilintide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Cagrilintide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Cagrilintide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cagrilintide-5mg-plus-semaglutide-5mg-blend",
    "title": "Cagrilintide 5mg+Semaglutide 5mg Blend",
    "aliases": [
      "Cagrilintide 5mg+Semaglutide 5mg Blend"
    ],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Cagrilintide 5mg+Semaglutide 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cagrilintide + Semaglutide Blend tracking should emphasize repeatability so your clinician can separate trend from noise quickly. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Cagrilintide + Semaglutide Blend, protocol moves are safer when escalation is tied to documented tolerance windows. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Cagrilintide + Semaglutide Blend so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Cagrilintide + Semaglutide Blend protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C1]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C1]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C2]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Cagrilintide + Semaglutide Blend dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Cagrilintide + Semaglutide Blend titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cagrilintide%205mg%2BSemaglutide%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cagrilintide%205mg%2BSemaglutide%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Cagrilintide + Semaglutide Blend",
    "subtitle": "Cagrilintide + Semaglutide blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Cagrilintide",
        "amount": "5mg"
      },
      {
        "name": "Semaglutide",
        "amount": "5mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Cagrilintide + Semaglutide Blend is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Cagrilintide + Semaglutide Blend is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Cagrilintide + Semaglutide Blend dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Cagrilintide + Semaglutide Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cagrisema",
    "title": "CagriSema",
    "aliases": [
      "Cagrilintide + Semaglutide"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CagriSema guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "CagriSema is not just Semaglutide plus one more thing. Combination therapies can change both appetite dynamics and side-effect profile, so this guide emphasizes structured comparison across cycles.",
    "dosingSection": {
      "overview": "CagriSema requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for CagriSema so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most CagriSema protocols are paced slowly, with escalation only after multi-week tolerance review. [C3]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C4]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C1]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C4]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C1]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C2]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each CagriSema dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "CagriSema may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should CagriSema titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CagriSema: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CagriSema",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CagriSema: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CagriSema",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CagriSema: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CagriSema",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CagriSema: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CagriSema+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "CagriSema",
    "subtitle": "Combination pathway guide for layered appetite and tolerance patterns.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "CagriSema is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "CagriSema is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each CagriSema dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for CagriSema often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "calcium",
    "title": "Calcium",
    "aliases": [
      "Ca"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Calcium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Calcium works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Calcium decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Calcium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Calcium, real-world dosing usually works best when baseline status is measured before aggressive correction. [C1]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C2]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C3]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C2]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C3]",
        "Re-check objective markers before extending high-intensity phases. [C1]"
      ]
    },
    "trackingSignals": [
      "Track Calcium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Calcium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Calcium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Calcium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Calcium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Calcium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Calcium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Calcium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Calcium is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Calcium should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Calcium timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Calcium often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cerebrolysin",
    "title": "Cerebrolysin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Cerebrolysin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cerebrolysin belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Cerebrolysin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Cerebrolysin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Cerebrolysin is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log Cerebrolysin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Cerebrolysin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Cerebrolysin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cerebrolysin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cerebrolysin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cerebrolysin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cerebrolysin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cerebrolysin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Cerebrolysin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Cerebrolysin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Cerebrolysin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Cerebrolysin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Cerebrolysin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Cerebrolysin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "chloride",
    "title": "Chloride",
    "aliases": [
      "Cl"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Chloride guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Chloride looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Chloride decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Chloride schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Chloride, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Chloride timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Chloride, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Chloride: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/list-all/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Chloride: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Chloride",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Chloride: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Chloride+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Chloride",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Chloride is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Chloride should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Chloride timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Chloride often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "chromium",
    "title": "Chromium",
    "aliases": [
      "Cr"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Chromium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Chromium works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Chromium decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Chromium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Chromium, real-world dosing usually works best when baseline status is measured before aggressive correction. [C1]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C2]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C3]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C2]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C3]",
        "Re-check objective markers before extending high-intensity phases. [C1]"
      ]
    },
    "trackingSignals": [
      "Track Chromium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Chromium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Chromium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Chromium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Chromium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Chromium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Chromium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Chromium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Chromium is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Chromium should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Chromium timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Chromium often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cjc-1295",
    "title": "CJC-1295",
    "aliases": [
      "CJC1295 (no DAC)",
      "CJC-1295 Without DAC"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Non-DAC CJC-1295 is timing-sensitive in practice. If you stack it, you need explicit stack metadata in every meaningful note.",
    "dosingSection": {
      "overview": "CJC-1295 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for CJC-1295 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "CJC-1295 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C4]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C4]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log CJC-1295 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "CJC-1295 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for CJC-1295 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CJC-1295",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CJC-1295: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "CJC-1295",
    "subtitle": "CJC-1295 non-DAC cadence guide for stack-aware tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "CJC-1295 is often approached as investigational support with variable evidence depth and variable product quality.",
      "CJC-1295 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "CJC-1295 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log CJC-1295 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for CJC-1295 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cjc-1295-without-dac-5mg-plus-ipa-5mg-blend",
    "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend",
    "aliases": [
      "CJC-1295 without DAC 5mg + IPA 5mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 without DAC 5mg + IPA 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "CJC 1295 Without DAC + Ipamorelin Blend belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "CJC 1295 Without DAC + Ipamorelin Blend requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat CJC 1295 Without DAC + Ipamorelin Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "CJC 1295 Without DAC + Ipamorelin Blend is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Blend protocols are typically interpreted component-by-component so one reaction does not misclassify the entire stack. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log CJC 1295 Without DAC + Ipamorelin Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "CJC 1295 Without DAC + Ipamorelin Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for CJC 1295 Without DAC + Ipamorelin Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295%20without%20DAC%205mg%20%2B%20IPA%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20without%20DAC%205mg%20%2B%20IPA%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "CJC 1295 Without DAC + Ipamorelin Blend",
    "subtitle": "CJC 1295 Without DAC + Ipamorelin blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "CJC 1295 Without DAC",
        "amount": "5mg"
      },
      {
        "name": "Ipamorelin",
        "amount": "5mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "CJC 1295 Without DAC + Ipamorelin Blend is often approached as investigational support with variable evidence depth and variable product quality.",
      "CJC 1295 Without DAC + Ipamorelin Blend is a blend, so interpretation should stay component-aware instead of treating every response as one signal.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "CJC 1295 Without DAC + Ipamorelin Blend should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log CJC 1295 Without DAC + Ipamorelin Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for CJC 1295 Without DAC + Ipamorelin Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cjc-dac",
    "title": "CJC-1295 DAC",
    "aliases": [
      "CJC-DAC",
      "CJC-1295 With DAC"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 DAC guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "CJC-DAC discussions should include cycle boundaries up front. Longer-acting compounds demand cleaner stop criteria and clearer reassessment checkpoints.",
    "dosingSection": {
      "overview": "CJC-1295 DAC should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for CJC-1295 DAC and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "CJC-1295 DAC is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C4]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C4]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log CJC-1295 DAC timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "CJC-1295 DAC may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for CJC-1295 DAC versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295 DAC: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20DAC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295 DAC: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CJC-1295%20DAC",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295 DAC: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20DAC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CJC-1295 DAC: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295%20DAC+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "CJC-1295 DAC",
    "subtitle": "Longer-acting CJC-DAC overview with cycle-boundary safeguards.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "CJC-1295 DAC is often approached as investigational support with variable evidence depth and variable product quality.",
      "CJC-1295 DAC is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "CJC-1295 DAC should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log CJC-1295 DAC timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for CJC-1295 DAC often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "clenbuterol",
    "title": "CLENBUTEROL",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CLENBUTEROL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "CLENBUTEROL should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For CLENBUTEROL, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for CLENBUTEROL and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most CLENBUTEROL users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact CLENBUTEROL timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "CLENBUTEROL may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is CLENBUTEROL appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CLENBUTEROL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CLENBUTEROL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CLENBUTEROL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CLENBUTEROL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CLENBUTEROL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "CLENBUTEROL",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "CLENBUTEROL is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "CLENBUTEROL should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact CLENBUTEROL timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for CLENBUTEROL often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "clomid",
    "title": "Clomid",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Clomid guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Clomid tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Clomid, stable cadence is the foundation for any useful adjustment discussion. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Clomid and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Clomid users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Clomid timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Clomid appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Clomid: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Clomid",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Clomid: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Clomid",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Clomid: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Clomid",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Clomid is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Clomid should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Clomid timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Clomid often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "cock-bombs",
    "title": "COCK BOMBS",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "COCK BOMBS guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "COCK BOMBS belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "COCK BOMBS should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for COCK BOMBS and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most COCK BOMBS users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact COCK BOMBS timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "COCK BOMBS may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is COCK BOMBS appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "COCK BOMBS: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=COCK%20BOMBS",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "COCK BOMBS: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=COCK%20BOMBS",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "COCK BOMBS: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "COCK BOMBS",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "COCK BOMBS is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "COCK BOMBS should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact COCK BOMBS timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for COCK BOMBS often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "copper",
    "title": "Copper",
    "aliases": [
      "Cu"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Copper guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Copper looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Copper decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Copper schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Copper, real-world dosing usually works best when baseline status is measured before aggressive correction. [C3]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C1]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C2]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C1]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C2]",
        "Re-check objective markers before extending high-intensity phases. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Copper timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Copper, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Copper: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Copper: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Copper",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Copper: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Copper+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Copper",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Copper is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Copper should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Copper timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Copper often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "d320",
    "title": "D320",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "D320 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "D320 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For D320, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for D320 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "D320 outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact D320 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "D320 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is D320 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "D320: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=D320",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "D320: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=D320",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "D320: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "D320",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "D320 is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "D320 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact D320 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for D320 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "danuglipron",
    "title": "Danuglipron",
    "aliases": [
      "PF-06882961"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Danuglipron guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Danuglipron has generated interest because it is oral, but route convenience does not reduce uncertainty. Log adherence and side effects tightly if it ever enters your care discussions.",
    "dosingSection": {
      "overview": "Danuglipron requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Danuglipron so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Danuglipron protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C4]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C4]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C1]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Danuglipron dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Danuglipron may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Danuglipron titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Danuglipron: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Danuglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Danuglipron: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Danuglipron",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Danuglipron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Danuglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Danuglipron: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Danuglipron+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Danuglipron",
    "subtitle": "Investigational oral incretin context and adherence framing.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "GLP-1/GIP",
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Danuglipron is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Danuglipron is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Danuglipron dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Danuglipron often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "deca-nd",
    "title": "DECA(ND)",
    "aliases": [
      "DECA(ND)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DECA(ND) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For DECA, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "DECA should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DECA and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "DECA outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact DECA timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DECA may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DECA appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DECA(ND): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DECA",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DECA(ND): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DECA",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DECA(ND): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DECA",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "DECA is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "DECA should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact DECA timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for DECA often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dermorphin",
    "title": "Dermorphin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Dermorphin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Dermorphin belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Dermorphin requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Dermorphin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Dermorphin is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log Dermorphin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Dermorphin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Dermorphin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dermorphin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dermorphin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dermorphin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dermorphin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dermorphin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Dermorphin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Dermorphin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Dermorphin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Dermorphin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Dermorphin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Dermorphin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dhb-1-test-cyp",
    "title": "DHB(1-Test Cyp)",
    "aliases": [
      "DHB(1-Test Cyp)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DHB(1-Test Cyp) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For DHB, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "DHB requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DHB and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most DHB users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact DHB timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DHB may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DHB appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DHB(1-Test Cyp): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DHB(1-Test Cyp): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DHB(1-Test Cyp): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DHB",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "DHB is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "DHB should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact DHB timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for DHB often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dht-stanolone",
    "title": "DHT (Stanolone)",
    "aliases": [
      "DHT (Stanolone)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DHT (Stanolone) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DHT should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "DHT requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DHT and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "DHT outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact DHT timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DHT may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DHT appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DHT (Stanolone): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DHT",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DHT (Stanolone): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DHT",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DHT (Stanolone): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DHT",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "DHT is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "DHT should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact DHT timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for DHT often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dianabol",
    "title": "DIANABOL",
    "aliases": [
      "DIANABOL(Methandrostenolone)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DIANABOL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DIANABOL should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "DIANABOL should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DIANABOL and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most DIANABOL users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact DIANABOL timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DIANABOL may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DIANABOL appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DIANABOL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DIANABOL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DIANABOL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DIANABOL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DIANABOL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DIANABOL",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "DIANABOL is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "DIANABOL should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact DIANABOL timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for DIANABOL often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dihexa",
    "title": "Dihexa",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Dihexa guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Dihexa, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Dihexa, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Dihexa and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Dihexa users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Dihexa timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Dihexa may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Dihexa appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dihexa: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dihexa",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dihexa: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dihexa",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dihexa: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Dihexa",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Dihexa is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Dihexa should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Dihexa timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Dihexa often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dnp",
    "title": "DNP",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DNP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For DNP, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For DNP, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DNP and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most DNP users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact DNP timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "DNP may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DNP appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DNP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DNP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DNP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DNP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DNP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DNP",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "DNP is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "DNP should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact DNP timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for DNP often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dsip",
    "title": "DSIP",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DSIP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DSIP belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "DSIP requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for DSIP and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "DSIP is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log DSIP timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "DSIP may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for DSIP versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DSIP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DSIP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DSIP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DSIP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DSIP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "DSIP",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "DSIP is often approached as investigational support with variable evidence depth and variable product quality.",
      "DSIP is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "DSIP should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log DSIP timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for DSIP often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dulaglutide",
    "title": "Dulaglutide",
    "aliases": [
      "Trulicity"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Dulaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Dulaglutide rewards routine. If your logs keep shifting day-to-day, you lose the trend. This guide helps you keep adherence, GI response, and weight trajectory readable over long windows.",
    "dosingSection": {
      "overview": "For Dulaglutide, protocol moves are safer when escalation is tied to documented tolerance windows. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Dulaglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Dulaglutide protocols are paced slowly, with escalation only after multi-week tolerance review. [C3]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C4]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C1]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C4]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C1]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C2]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Dulaglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Dulaglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dulaglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Dulaglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dulaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dulaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dulaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dulaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Dulaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dulaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Dulaglutide",
    "subtitle": "Long-acting weekly GLP-1 with consistency-first tracking priorities.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Dulaglutide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Dulaglutide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Dulaglutide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Dulaglutide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "dutasteride",
    "title": "Dutasteride",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Dutasteride guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Dutasteride tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With Dutasteride, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Dutasteride and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Dutasteride users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Dutasteride timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Dutasteride appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dutasteride: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dutasteride",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dutasteride: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dutasteride",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dutasteride: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Dutasteride",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Dutasteride is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Dutasteride should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Dutasteride timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Dutasteride often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ecnoglutide",
    "title": "Ecnoglutide",
    "aliases": [
      "XW003"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ecnoglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Ecnoglutide belongs in a risk-managed conversation, not a shortcut conversation. Keep objective markers and escalation boundaries explicit.",
    "dosingSection": {
      "overview": "Ecnoglutide requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Ecnoglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Ecnoglutide protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C4]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C4]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C1]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Ecnoglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Ecnoglutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Ecnoglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ecnoglutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Ecnoglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ecnoglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ecnoglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ecnoglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ecnoglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Ecnoglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ecnoglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Ecnoglutide",
    "subtitle": "Research-stage metabolic peptide with protocol-boundary emphasis.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Ecnoglutide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Ecnoglutide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Ecnoglutide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Ecnoglutide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "efpeglenatide",
    "title": "Efpeglenatide",
    "aliases": [
      "AMG 133 (historical context)"
    ],
    "category": "GLP-1",
    "status": "discontinued",
    "statusLabel": "Discontinued/Legacy",
    "metaDescription": "Efpeglenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Efpeglenatide is best handled as a historical or legacy reference. Verify what is current, what is discontinued, and what is still clinically relevant before drawing conclusions.",
    "dosingSection": {
      "overview": "For Efpeglenatide, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Efpeglenatide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Efpeglenatide protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C4]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C4]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C1]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Efpeglenatide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Efpeglenatide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Efpeglenatide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Efpeglenatide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Efpeglenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Efpeglenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Efpeglenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Efpeglenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Efpeglenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Efpeglenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Efpeglenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Efpeglenatide",
    "subtitle": "Legacy/discontinued pathway with source-verification focus.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Discontinued"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Efpeglenatide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Discontinued/Legacy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Efpeglenatide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Efpeglenatide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Efpeglenatide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "epithalon",
    "title": "Epithalon",
    "aliases": [
      "Epitalon"
    ],
    "category": "Anti-Aging Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Epithalon guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Epithalon is often discussed with sweeping longevity claims. This page is intentionally practical: track what can be observed and avoid storytelling leaps.",
    "dosingSection": {
      "overview": "Epithalon requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Epithalon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Epithalon is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C4]"
      ]
    },
    "trackingSignals": [
      "Log Epithalon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Epithalon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Epithalon versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Epithalon: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Epithalon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Epithalon: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Epithalon",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Epithalon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Epithalon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Epithalon: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Epithalon+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Epithalon",
    "subtitle": "Epithalon anti-aging peptide context with evidence realism.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Epithalon is often approached as investigational support with variable evidence depth and variable product quality.",
      "Epithalon is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Epithalon should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Epithalon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Epithalon often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "epo",
    "title": "EPO",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "EPO guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "EPO belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For EPO, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for EPO and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "EPO is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log EPO timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "EPO may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for EPO versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "EPO: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=EPO",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "EPO: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=EPO",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "EPO: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "EPO",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "EPO is often approached as investigational support with variable evidence depth and variable product quality.",
      "EPO is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "EPO should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log EPO timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for EPO often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "estradial-cypionate",
    "title": "Estradial Cypionate",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Estradial Cypionate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Estradial Cypionate should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Estradial Cypionate requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Estradial Cypionate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Estradial Cypionate outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Estradial Cypionate timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Estradial Cypionate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Estradial Cypionate appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Estradial Cypionate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Estradial%20Cypionate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Estradial Cypionate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Estradial%20Cypionate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Estradial Cypionate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Estradial Cypionate",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Estradial Cypionate is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Estradial Cypionate should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Estradial Cypionate timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Estradial Cypionate often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "exenatide",
    "title": "Exenatide",
    "aliases": [
      "Byetta",
      "Bydureon"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Exenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Exenatide has two very different use patterns. If your notes do not reflect formulation and schedule differences, trend interpretation breaks. This guide keeps those pathways separate and clear.",
    "dosingSection": {
      "overview": "Exenatide should be reviewed over structured intervals, not single difficult days. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Exenatide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Exenatide protocols are paced slowly, with escalation only after multi-week tolerance review. [C4]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C1]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C2]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C1]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C2]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Exenatide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Exenatide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Exenatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Exenatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Exenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Exenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Exenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Exenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Exenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Exenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Exenatide",
    "subtitle": "Immediate vs extended-release GLP-1 workflow distinctions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Exenatide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Exenatide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Exenatide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Exenatide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "finasteride",
    "title": "Finasteride",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Finasteride guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Finasteride is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Finasteride protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Finasteride and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Finasteride users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Finasteride timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Finasteride appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Finasteride: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Finasteride",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Finasteride: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Finasteride",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Finasteride: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Finasteride",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Finasteride is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Finasteride should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Finasteride timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Finasteride often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "flibanserin",
    "title": "Flibanserin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Flibanserin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Flibanserin, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Flibanserin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Flibanserin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Flibanserin users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Flibanserin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Flibanserin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Flibanserin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Flibanserin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Flibanserin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Flibanserin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Flibanserin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Flibanserin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Flibanserin",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Flibanserin is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Flibanserin should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Flibanserin timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Flibanserin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "fluoxymesterone-halotestin",
    "title": "Fluoxymesterone(Halotestin)",
    "aliases": [
      "Fluoxymesterone(Halotestin)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Fluoxymesterone(Halotestin) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Fluoxymesterone, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Fluoxymesterone requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Fluoxymesterone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Fluoxymesterone users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Fluoxymesterone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Fluoxymesterone may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Fluoxymesterone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Fluoxymesterone(Halotestin): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Fluoxymesterone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Fluoxymesterone(Halotestin): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Fluoxymesterone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Fluoxymesterone(Halotestin): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Fluoxymesterone",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Fluoxymesterone is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Fluoxymesterone should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Fluoxymesterone timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Fluoxymesterone often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "follistatin",
    "title": "Follistatin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Follistatin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Follistatin should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Follistatin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Follistatin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Follistatin is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Follistatin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Follistatin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Follistatin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Follistatin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Follistatin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Follistatin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Follistatin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Follistatin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Follistatin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Follistatin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Follistatin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Follistatin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Follistatin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Follistatin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "foxo4",
    "title": "FOXO4",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "FOXO4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For FOXO4, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "FOXO4 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for FOXO4 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "FOXO4 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log FOXO4 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "FOXO4 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for FOXO4 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "FOXO4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=FOXO4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "FOXO4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=FOXO4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "FOXO4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "FOXO4",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "FOXO4 is often approached as investigational support with variable evidence depth and variable product quality.",
      "FOXO4 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "FOXO4 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log FOXO4 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for FOXO4 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "fragment-176-191",
    "title": "Fragment 176-191",
    "aliases": [
      "HGH Fragment 176-191"
    ],
    "category": "Fat Loss Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Fragment 176-191 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Fragment 176-191 is often marketed aggressively. This guide is built to keep claims grounded and to separate tracking evidence from narrative momentum.",
    "dosingSection": {
      "overview": "For Fragment 176-191, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Fragment 176-191 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Fragment 176-191 is usually paced conservatively in real-world use due to evidence and quality variability. [C4]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Fragment 176-191 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Fragment 176-191 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Fragment 176-191 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Fragment 176-191: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Fragment%20176-191",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Fragment 176-191: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Fragment%20176-191",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Fragment 176-191: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Fragment%20176-191",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Fragment 176-191: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Fragment%20176-191+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Fragment 176-191",
    "subtitle": "Fat-loss peptide context with strict expectation management.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Fragment 176-191 is often approached as investigational support with variable evidence depth and variable product quality.",
      "Fragment 176-191 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Fragment 176-191 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Fragment 176-191 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Fragment 176-191 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "gaz",
    "title": "GAZ",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GAZ guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For GAZ, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "GAZ requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GAZ and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "GAZ outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact GAZ timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "GAZ may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GAZ appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GAZ: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GAZ",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GAZ: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GAZ",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GAZ: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GAZ",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "GAZ is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "GAZ should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact GAZ timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for GAZ often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ghk-cu",
    "title": "GHK-CU",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHK-CU guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GHK-CU appears in many formulations. The useful work is documenting route, formulation, and response timeline clearly enough to compare cycles.",
    "dosingSection": {
      "overview": "For GHK-CU, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHK-CU and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "GHK-CU is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log GHK-CU timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHK-CU may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHK-CU versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHK-CU: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHK-CU: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHK-CU: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GHK-CU",
    "subtitle": "GHK-CU support guide with route and response-context tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "GHK-CU is often approached as investigational support with variable evidence depth and variable product quality.",
      "GHK-CU is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "GHK-CU should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log GHK-CU timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for GHK-CU often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ghrp-2",
    "title": "GHRP-2",
    "aliases": [
      "Growth Hormone Releasing Peptide-2"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-2 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "GHRP-2 can shift appetite and stress-response perception quickly. This guide emphasizes structured symptom timing so interpretation stays anchored.",
    "dosingSection": {
      "overview": "GHRP-2 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHRP-2 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "GHRP-2 is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C4]"
      ]
    },
    "trackingSignals": [
      "Log GHRP-2 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHRP-2 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHRP-2 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-2: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-2: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=GHRP-2",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-2: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "GHRP-2: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-2+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "GHRP-2",
    "subtitle": "GHRP-2 context with appetite and tolerance monitoring priorities.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "GHRP-2 is often approached as investigational support with variable evidence depth and variable product quality.",
      "GHRP-2 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "GHRP-2 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log GHRP-2 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for GHRP-2 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ghrp-2-acetate",
    "title": "GHRP-2 Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-2 Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For GHRP-2 Acetate, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "GHRP-2 Acetate requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHRP-2 Acetate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "GHRP-2 Acetate is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log GHRP-2 Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHRP-2 Acetate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHRP-2 Acetate versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-2 Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-2%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-2 Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-2 Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GHRP-2 Acetate",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "GHRP-2 Acetate is often approached as investigational support with variable evidence depth and variable product quality.",
      "GHRP-2 Acetate is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "GHRP-2 Acetate should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log GHRP-2 Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for GHRP-2 Acetate often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ghrp-6",
    "title": "GHRP-6",
    "aliases": [
      "Growth Hormone Releasing Peptide-6"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-6 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "GHRP-6 often changes hunger signaling in ways users underestimate. Good logs here are about timing and magnitude, not just yes or no effects.",
    "dosingSection": {
      "overview": "For GHRP-6, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHRP-6 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "GHRP-6 is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C4]"
      ]
    },
    "trackingSignals": [
      "Log GHRP-6 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHRP-6 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHRP-6 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-6: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-6: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=GHRP-6",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-6: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "GHRP-6: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-6+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "GHRP-6",
    "subtitle": "GHRP-6 tracking guide with hunger-signal framing.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "GHRP-6 is often approached as investigational support with variable evidence depth and variable product quality.",
      "GHRP-6 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "GHRP-6 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log GHRP-6 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for GHRP-6 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ghrp-6-acetate",
    "title": "GHRP-6 Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-6 Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For GHRP-6 Acetate, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For GHRP-6 Acetate, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GHRP-6 Acetate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "GHRP-6 Acetate is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log GHRP-6 Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GHRP-6 Acetate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GHRP-6 Acetate versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-6 Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-6%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-6 Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-6 Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GHRP-6 Acetate",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "GHRP-6 Acetate is often approached as investigational support with variable evidence depth and variable product quality.",
      "GHRP-6 Acetate is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "GHRP-6 Acetate should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log GHRP-6 Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for GHRP-6 Acetate often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "glow-ghk-cu-50mg-plus-tb500-10mg-plus-bpc157-10mg-blend",
    "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend",
    "aliases": [
      "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GLOW is a vendor-named blend, so clarity comes from component-level tracking. Treat it as three interacting signals, not one monolithic effect.",
    "dosingSection": {
      "overview": "GLOW requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat GLOW as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "GLOW is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Blend protocols are typically interpreted component-by-component so one reaction does not misclassify the entire stack. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log GLOW timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "GLOW may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for GLOW versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GLOW",
    "subtitle": "GHK-CU + TB-500 + BPC-157 blend.",
    "acronymInfo": {
      "code": "GLOW",
      "meaning": null,
      "isVendorDefined": true,
      "note": "Vendor acronym; full expansion not published in source material."
    },
    "composition": [
      {
        "name": "GHK-CU",
        "amount": "50mg"
      },
      {
        "name": "TB-500",
        "amount": "10mg"
      },
      {
        "name": "BPC-157",
        "amount": "10mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "GLOW is often approached as investigational support with variable evidence depth and variable product quality.",
      "GLOW is a blend, so interpretation should stay component-aware instead of treating every response as one signal.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "GLOW should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log GLOW timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for GLOW often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "glutathione",
    "title": "Glutathione",
    "aliases": [
      "GSH"
    ],
    "category": "Antioxidant",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Glutathione guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Glutathione tracking is most useful when you include formulation, handling, and timing details that usually get skipped in casual notes.",
    "dosingSection": {
      "overview": "For Glutathione, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Glutathione and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Glutathione is usually handled with conservative adjustments and scheduled trend reviews. [C1]",
        "Keeping one-variable changes per review window is a common tactic to protect interpretation quality. [C2]",
        "Consistent logging windows are typically more useful than high-volume unscheduled notes. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C4]"
      ]
    },
    "trackingSignals": [
      "Document exact Glutathione timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Glutathione appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Glutathione: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Glutathione&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Glutathione: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Glutathione",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Glutathione: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Glutathione",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Glutathione: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Glutathione+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Glutathione",
    "subtitle": "Glutathione support guide with formulation and handling context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Glutathione should be framed as a targeted support tool with explicit goals and an exit plan.",
      "The protocol should be reviewed against objective logs rather than day-to-day mood shifts.",
      "Most users benefit from conservative pacing and early review when side effects cluster."
    ],
    "candidateProfile": [
      "Users with a clear reason for use and clinician oversight for higher-risk decisions.",
      "People who can keep objective logs and review them on a fixed schedule.",
      "Patients ready to de-escalate when risk rises faster than benefit."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI or appetite shifts during early adaptation windows.",
        "Mild headache, fatigue, or day-to-day symptom variability.",
        "Transient tolerance changes when schedule consistency drops."
      ],
      "serious": [
        "Rapidly escalating symptoms after dose changes.",
        "Severe dehydration, confusion, or inability to maintain intake.",
        "Allergic reactions with breathing difficulty or swelling."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Glutathione should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Glutathione timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with a clear reason for use and clinician oversight for higher-risk decisions.",
        "People who can keep objective logs and review them on a fixed schedule.",
        "Patients ready to de-escalate when risk rises faster than benefit.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI or appetite shifts during early adaptation windows.",
        "Mild headache, fatigue, or day-to-day symptom variability.",
        "Transient tolerance changes when schedule consistency drops."
      ],
      "sideEffectsSerious": [
        "Rapidly escalating symptoms after dose changes.",
        "Severe dehydration, confusion, or inability to maintain intake.",
        "Allergic reactions with breathing difficulty or swelling."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Glutathione often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "gonadorelin",
    "title": "Gonadorelin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Gonadorelin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "With gonadorelin, context is everything: baseline axis status, intended objective, and lab timing all matter more than anecdote quality.",
    "dosingSection": {
      "overview": "Gonadorelin decisions should follow objective trend checks, not reactive day-to-day interpretation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Gonadorelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Gonadorelin plans are commonly anchored to regular lab checkpoints rather than symptom-only adjustments. [C1]",
        "Real-world teams often avoid simultaneous multi-compound changes so response remains interpretable. [C2]",
        "Dose timing consistency is a major determinant of stable trend interpretation. [C3]"
      ],
      "escalationBoundaries": [
        "Stop ad-hoc escalation when lab trends or blood-pressure/symptom signals become unstable. [C2]",
        "Avoid adding new hormone-active agents in the same window as dose escalation. [C3]",
        "Escalate only after objective review confirms benefit exceeds current risk. [C1]"
      ]
    },
    "trackingSignals": [
      "Log Gonadorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Gonadorelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Gonadorelin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Gonadorelin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Gonadorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Gonadorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Gonadorelin: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Gonadorelin",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Gonadorelin",
    "subtitle": "Gonadorelin guide with hormone-axis monitoring checkpoints.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Hormone",
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Gonadorelin is typically discussed for endocrine goals that require baseline labs and regular follow-up.",
      "Benefit and risk are driven by how well labs, symptoms, and timing are tracked together.",
      "Dose changes usually belong inside a supervised plan rather than ad-hoc cycle edits."
    ],
    "candidateProfile": [
      "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
      "People able to complete repeat labs and clinical follow-up on schedule.",
      "Users who can avoid stacking multiple endocrine-active compounds at the same time."
    ],
    "avoidanceFlags": [
      "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
      "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "serious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Gonadorelin should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Log Gonadorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
        "People able to complete repeat labs and clinical follow-up on schedule.",
        "Users who can avoid stacking multiple endocrine-active compounds at the same time.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
        "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "sideEffectsSerious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Gonadorelin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "gw-501516-cardarine",
    "title": "GW-501516(Cardarine)",
    "aliases": [
      "GW-501516(Cardarine)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GW-501516(Cardarine) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GW-501516 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For GW-501516, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for GW-501516 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most GW-501516 users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact GW-501516 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "GW-501516 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GW-501516 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GW-501516(Cardarine): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GW-501516",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GW-501516(Cardarine): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GW-501516",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GW-501516(Cardarine): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "GW-501516",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "GW-501516 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "GW-501516 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact GW-501516 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for GW-501516 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "hcg",
    "title": "Human Chorionic Gonadotropin (HCG)",
    "aliases": [
      "Pregnyl",
      "Ovidrel",
      "HCG",
      "Human Chorionic Gonadotropin (HCG)"
    ],
    "category": "Hormone",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Human Chorionic Gonadotropin (HCG) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "HCG tracking only becomes useful when dose schedule and lab cadence are aligned. This page keeps those two systems connected so trend review stays meaningful.",
    "dosingSection": {
      "overview": "Human Chorionic Gonadotropin should be reviewed over structured intervals, not single difficult days. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Human Chorionic Gonadotropin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Human Chorionic Gonadotropin plans are commonly anchored to regular lab checkpoints rather than symptom-only adjustments. [C3]",
        "Real-world teams often avoid simultaneous multi-compound changes so response remains interpretable. [C4]",
        "Dose timing consistency is a major determinant of stable trend interpretation. [C1]"
      ],
      "escalationBoundaries": [
        "Stop ad-hoc escalation when lab trends or blood-pressure/symptom signals become unstable. [C4]",
        "Avoid adding new hormone-active agents in the same window as dose escalation. [C1]",
        "Escalate only after objective review confirms benefit exceeds current risk. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Human Chorionic Gonadotropin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Human Chorionic Gonadotropin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Human Chorionic Gonadotropin (HCG): FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Human%20Chorionic%20Gonadotropin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Human Chorionic Gonadotropin (HCG): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Human%20Chorionic%20Gonadotropin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Human Chorionic Gonadotropin (HCG): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Human%20Chorionic%20Gonadotropin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Human Chorionic Gonadotropin (HCG): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Human%20Chorionic%20Gonadotropin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Human Chorionic Gonadotropin",
    "subtitle": "HCG hormone-support workflow with schedule and lab alignment.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Human Chorionic Gonadotropin is typically discussed for endocrine goals that require baseline labs and regular follow-up.",
      "Benefit and risk are driven by how well labs, symptoms, and timing are tracked together.",
      "Dose changes usually belong inside a supervised plan rather than ad-hoc cycle edits."
    ],
    "candidateProfile": [
      "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
      "People able to complete repeat labs and clinical follow-up on schedule.",
      "Users who can avoid stacking multiple endocrine-active compounds at the same time."
    ],
    "avoidanceFlags": [
      "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
      "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "serious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Human Chorionic Gonadotropin should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Human Chorionic Gonadotropin timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
        "People able to complete repeat labs and clinical follow-up on schedule.",
        "Users who can avoid stacking multiple endocrine-active compounds at the same time.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
        "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "sideEffectsSerious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Human Chorionic Gonadotropin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "hexarelin",
    "title": "Hexarelin",
    "aliases": [
      "Examorelin"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Hexarelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Hexarelin gets attention for potency, but that is exactly why the risk conversation matters. This guide favors conservative cycles and clear reassessment points.",
    "dosingSection": {
      "overview": "Hexarelin requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Hexarelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Hexarelin is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C4]"
      ]
    },
    "trackingSignals": [
      "Log Hexarelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Hexarelin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Hexarelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Hexarelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Hexarelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Hexarelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Hexarelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Hexarelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Hexarelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Hexarelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Hexarelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Hexarelin",
    "subtitle": "Potent secretagogue context with desensitization caution framing.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Hexarelin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Hexarelin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Hexarelin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Hexarelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Hexarelin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "hgh-191aa-somatropin",
    "title": "HGH 191AA (Somatropin)",
    "aliases": [
      "HGH 191AA (Somatropin)"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HGH 191AA (Somatropin) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "HGH 191AA should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For HGH 191AA, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for HGH 191AA and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "HGH 191AA is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log HGH 191AA timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "HGH 191AA may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for HGH 191AA versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HGH 191AA (Somatropin): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HGH%20191AA",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HGH 191AA (Somatropin): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HGH%20191AA",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HGH 191AA (Somatropin): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "HGH 191AA",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "HGH 191AA is often approached as investigational support with variable evidence depth and variable product quality.",
      "HGH 191AA is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "HGH 191AA should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log HGH 191AA timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for HGH 191AA often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "hhb",
    "title": "HHB",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HHB guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "HHB belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "HHB should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for HHB and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "HHB outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact HHB timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "HHB may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is HHB appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HHB: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HHB: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HHB: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "HHB",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "HHB is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "HHB should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact HHB timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for HHB often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "hmg",
    "title": "HMG",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HMG guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For HMG, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For HMG, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for HMG and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "HMG plans are commonly anchored to regular lab checkpoints rather than symptom-only adjustments. [C1]",
        "Real-world teams often avoid simultaneous multi-compound changes so response remains interpretable. [C2]",
        "Dose timing consistency is a major determinant of stable trend interpretation. [C3]"
      ],
      "escalationBoundaries": [
        "Stop ad-hoc escalation when lab trends or blood-pressure/symptom signals become unstable. [C2]",
        "Avoid adding new hormone-active agents in the same window as dose escalation. [C3]",
        "Escalate only after objective review confirms benefit exceeds current risk. [C1]"
      ]
    },
    "trackingSignals": [
      "Log HMG timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "HMG may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for HMG versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HMG: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HMG",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HMG: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HMG",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HMG: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "HMG",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "HMG is typically discussed for endocrine goals that require baseline labs and regular follow-up.",
      "Benefit and risk are driven by how well labs, symptoms, and timing are tracked together.",
      "Dose changes usually belong inside a supervised plan rather than ad-hoc cycle edits."
    ],
    "candidateProfile": [
      "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
      "People able to complete repeat labs and clinical follow-up on schedule.",
      "Users who can avoid stacking multiple endocrine-active compounds at the same time."
    ],
    "avoidanceFlags": [
      "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
      "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "serious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "HMG should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Log HMG timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
        "People able to complete repeat labs and clinical follow-up on schedule.",
        "Users who can avoid stacking multiple endocrine-active compounds at the same time.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
        "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "sideEffectsSerious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for HMG often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "hyaluronic-acid",
    "title": "Hyaluronic acid",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Hyaluronic acid guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Hyaluronic acid works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Hyaluronic acid should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Hyaluronic acid and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Hyaluronic acid is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Hyaluronic acid timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Hyaluronic acid versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Hyaluronic acid: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Hyaluronic%20acid",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Hyaluronic acid: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Hyaluronic%20acid",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Hyaluronic acid: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Hyaluronic%20acid",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Hyaluronic acid",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "support",
    "useCases": [
      "Hyaluronic acid is often approached as investigational support with variable evidence depth and variable product quality.",
      "Hyaluronic acid is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Hyaluronic acid should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Hyaluronic acid timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Hyaluronic acid often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "igf-1lr3",
    "title": "IGF-1LR3",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "IGF-1LR3 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "IGF-1LR3 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "IGF-1LR3 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for IGF-1LR3 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "IGF-1LR3 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log IGF-1LR3 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "IGF-1LR3 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for IGF-1LR3 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "IGF-1LR3: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=IGF-1LR3",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "IGF-1LR3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=IGF-1LR3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "IGF-1LR3: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "IGF-1LR3",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "IGF-1LR3 is often approached as investigational support with variable evidence depth and variable product quality.",
      "IGF-1LR3 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "IGF-1LR3 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log IGF-1LR3 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for IGF-1LR3 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "igf-des",
    "title": "IGF-DES",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "IGF-DES guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For IGF-DES, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "IGF-DES should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for IGF-DES and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "IGF-DES is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log IGF-DES timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "IGF-DES may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for IGF-DES versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "IGF-DES: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=IGF-DES",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "IGF-DES: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=IGF-DES",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "IGF-DES: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "IGF-DES",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "IGF-DES is often approached as investigational support with variable evidence depth and variable product quality.",
      "IGF-DES is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "IGF-DES should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log IGF-DES timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for IGF-DES often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "insulin",
    "title": "Insulin",
    "aliases": [
      "Humalog",
      "Novolog",
      "Lantus",
      "Tresiba"
    ],
    "category": "Insulin",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Insulin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Insulin belongs to a high-consequence category. This guide is built around safety infrastructure: glucose context, hypoglycemia handling, and clinician-directed adjustments.",
    "dosingSection": {
      "overview": "Insulin decisions should follow objective trend checks, not reactive day-to-day interpretation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Insulin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Insulin dosing is individualized around glucose data, meals, activity, and concurrent therapy context. [C3]",
        "Most safe insulin workflows use structured glucose logs before making any meaningful dose adjustment. [C4]",
        "Pattern-based review (same time windows across multiple days) is typically favored over isolated readings. [C1]"
      ],
      "escalationBoundaries": [
        "Treat recurrent low-glucose episodes as an immediate hold-and-review event, not a signal to continue escalation. [C4]",
        "Do not apply catch-up bolus corrections without a clinician-approved correction framework. [C1]",
        "Rapid glucose instability with neurologic or cardiopulmonary symptoms needs urgent medical evaluation. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Insulin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Insulin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Insulin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Insulin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Insulin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Insulin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Insulin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Insulin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Insulin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Insulin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Insulin",
    "subtitle": "Insulin high-stakes tracking guide with safety-first guardrails.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Insulin is typically discussed for endocrine goals that require baseline labs and regular follow-up.",
      "Benefit and risk are driven by how well labs, symptoms, and timing are tracked together.",
      "Dose changes usually belong inside a supervised plan rather than ad-hoc cycle edits."
    ],
    "candidateProfile": [
      "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
      "People able to complete repeat labs and clinical follow-up on schedule.",
      "Users who can avoid stacking multiple endocrine-active compounds at the same time."
    ],
    "avoidanceFlags": [
      "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
      "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "serious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Insulin should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Recurrent low-glucose risk signals or severe symptomatic instability require immediate hold-and-review with a clinician.",
        "Rapid glucose volatility with neurologic or cardiopulmonary symptoms requires urgent evaluation."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Insulin timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
        "People able to complete repeat labs and clinical follow-up on schedule.",
        "Users who can avoid stacking multiple endocrine-active compounds at the same time.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
        "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "sideEffectsSerious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Insulin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "iodine",
    "title": "Iodine",
    "aliases": [
      "I"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Iodine guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Iodine works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "For Iodine, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Keep Iodine schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Iodine, real-world dosing usually works best when baseline status is measured before aggressive correction. [C3]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C1]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C2]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C1]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C2]",
        "Re-check objective markers before extending high-intensity phases. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Iodine timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Iodine, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Iodine: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Iodine-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Iodine: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Iodine",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Iodine: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Iodine+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Iodine",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Iodine is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Iodine should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Iodine timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Iodine often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ipamorelin",
    "title": "Ipamorelin",
    "aliases": [
      "IPA"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ipamorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Ipamorelin logs get messy when timing floats. This guide centers dosing-window discipline and outcome notes that can survive clinician scrutiny.",
    "dosingSection": {
      "overview": "Ipamorelin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Ipamorelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Ipamorelin is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C4]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C4]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Ipamorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Ipamorelin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Ipamorelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ipamorelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Ipamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ipamorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ipamorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ipamorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ipamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Ipamorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ipamorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Ipamorelin",
    "subtitle": "GH secretagogue use-pattern guide with timing discipline.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Ipamorelin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Ipamorelin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Ipamorelin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Ipamorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Ipamorelin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "iron",
    "title": "Iron",
    "aliases": [
      "Fe"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Iron guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Iron works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Iron should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Iron schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Iron, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Iron timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Iron, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Iron: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Iron: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Iron",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Iron: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Iron+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Iron",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Iron is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Iron should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Iron timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Iron often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "isotretinoin",
    "title": "isotretinoin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "isotretinoin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "isotretinoin tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With isotretinoin, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for isotretinoin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most isotretinoin users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact isotretinoin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is isotretinoin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "isotretinoin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=isotretinoin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "isotretinoin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=isotretinoin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "isotretinoin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "isotretinoin",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "isotretinoin is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "isotretinoin should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact isotretinoin timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for isotretinoin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ivermectin",
    "title": "Ivermectin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ivermectin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Ivermectin should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Ivermectin requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Ivermectin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Ivermectin users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Ivermectin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Ivermectin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Ivermectin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ivermectin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ivermectin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ivermectin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ivermectin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ivermectin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Ivermectin",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Ivermectin is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Ivermectin should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Ivermectin timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Ivermectin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "kisspeptin-10",
    "title": "KissPeptin-10",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "KissPeptin-10 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Kisspeptin-10 should be treated as endocrine-context sensitive. This page emphasizes clinician-led interpretation and careful biomarker follow-up.",
    "dosingSection": {
      "overview": "For KissPeptin-10, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for KissPeptin-10 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "KissPeptin-10 plans are commonly anchored to regular lab checkpoints rather than symptom-only adjustments. [C1]",
        "Real-world teams often avoid simultaneous multi-compound changes so response remains interpretable. [C2]",
        "Dose timing consistency is a major determinant of stable trend interpretation. [C3]"
      ],
      "escalationBoundaries": [
        "Stop ad-hoc escalation when lab trends or blood-pressure/symptom signals become unstable. [C2]",
        "Avoid adding new hormone-active agents in the same window as dose escalation. [C3]",
        "Escalate only after objective review confirms benefit exceeds current risk. [C1]"
      ]
    },
    "trackingSignals": [
      "Log KissPeptin-10 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "KissPeptin-10 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for KissPeptin-10 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "KissPeptin-10: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=KissPeptin-10",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "KissPeptin-10: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=KissPeptin-10",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "KissPeptin-10: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "KissPeptin-10",
    "subtitle": "Kisspeptin-10 reference guide for hormone-axis discussions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "KissPeptin-10 is typically discussed for endocrine goals that require baseline labs and regular follow-up.",
      "Benefit and risk are driven by how well labs, symptoms, and timing are tracked together.",
      "Dose changes usually belong inside a supervised plan rather than ad-hoc cycle edits."
    ],
    "candidateProfile": [
      "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
      "People able to complete repeat labs and clinical follow-up on schedule.",
      "Users who can avoid stacking multiple endocrine-active compounds at the same time."
    ],
    "avoidanceFlags": [
      "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
      "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "serious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "KissPeptin-10 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Log KissPeptin-10 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
        "People able to complete repeat labs and clinical follow-up on schedule.",
        "Users who can avoid stacking multiple endocrine-active compounds at the same time.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
        "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "sideEffectsSerious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for KissPeptin-10 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "klow-ghk-cu-50mg-plus-tb500-10mg-plus-bpc157-10mg-plus-kpv-10mg-blend",
    "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend",
    "aliases": [
      "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "KLOW adds KPV into an already stacked blend, which increases interpretation complexity. This guide prioritizes disciplined logging and conservative conclusions.",
    "dosingSection": {
      "overview": "KLOW requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Treat KLOW as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "KLOW is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Blend protocols are typically interpreted component-by-component so one reaction does not misclassify the entire stack. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log KLOW timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "KLOW may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for KLOW versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%2BKPV%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%2BKPV%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "KLOW",
    "subtitle": "GHK-CU + TB-500 + BPC-157 + KPV blend.",
    "acronymInfo": {
      "code": "KLOW",
      "meaning": null,
      "isVendorDefined": true,
      "note": "Vendor acronym; full expansion not published in source material."
    },
    "composition": [
      {
        "name": "GHK-CU",
        "amount": "50mg"
      },
      {
        "name": "TB-500",
        "amount": "10mg"
      },
      {
        "name": "BPC-157",
        "amount": "10mg"
      },
      {
        "name": "KPV",
        "amount": "10mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "KLOW is often approached as investigational support with variable evidence depth and variable product quality.",
      "KLOW is a blend, so interpretation should stay component-aware instead of treating every response as one signal.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "KLOW should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log KLOW timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for KLOW often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "kpv",
    "title": "KPV",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "KPV guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "KPV claims are broad and often loosely defined. This guide keeps your notes actionable by anchoring symptom windows and protocol boundaries.",
    "dosingSection": {
      "overview": "For KPV, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for KPV and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "KPV is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log KPV timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "KPV may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for KPV versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "KPV: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=KPV",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "KPV: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=KPV",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "KPV: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "KPV",
    "subtitle": "KPV peptide context with symptom-window tracking priorities.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "KPV is often approached as investigational support with variable evidence depth and variable product quality.",
      "KPV is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "KPV should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log KPV timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for KPV often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "l-carnitine",
    "title": "L-Carnitine",
    "aliases": [
      "Levocarnitine"
    ],
    "category": "Amino Acid",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "L-Carnitine guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "L-carnitine can look straightforward until route-specific tolerance becomes the limiting factor. This page centers practical logging around that reality.",
    "dosingSection": {
      "overview": "L-Carnitine should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for L-Carnitine and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "L-Carnitine is usually handled with conservative adjustments and scheduled trend reviews. [C1]",
        "Keeping one-variable changes per review window is a common tactic to protect interpretation quality. [C2]",
        "Consistent logging windows are typically more useful than high-volume unscheduled notes. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C4]"
      ]
    },
    "trackingSignals": [
      "Document exact L-Carnitine timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is L-Carnitine appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "L-Carnitine: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:L-Carnitine&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "L-Carnitine: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=L-Carnitine",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "L-Carnitine: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=L-Carnitine",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "L-Carnitine: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=L-Carnitine+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "L-Carnitine",
    "subtitle": "L-carnitine support guide with route-tolerance focus.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "L-Carnitine should be framed as a targeted support tool with explicit goals and an exit plan.",
      "The protocol should be reviewed against objective logs rather than day-to-day mood shifts.",
      "Most users benefit from conservative pacing and early review when side effects cluster."
    ],
    "candidateProfile": [
      "Users with a clear reason for use and clinician oversight for higher-risk decisions.",
      "People who can keep objective logs and review them on a fixed schedule.",
      "Patients ready to de-escalate when risk rises faster than benefit."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI or appetite shifts during early adaptation windows.",
        "Mild headache, fatigue, or day-to-day symptom variability.",
        "Transient tolerance changes when schedule consistency drops."
      ],
      "serious": [
        "Rapidly escalating symptoms after dose changes.",
        "Severe dehydration, confusion, or inability to maintain intake.",
        "Allergic reactions with breathing difficulty or swelling."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "L-Carnitine should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact L-Carnitine timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with a clear reason for use and clinician oversight for higher-risk decisions.",
        "People who can keep objective logs and review them on a fixed schedule.",
        "Patients ready to de-escalate when risk rises faster than benefit.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI or appetite shifts during early adaptation windows.",
        "Mild headache, fatigue, or day-to-day symptom variability.",
        "Transient tolerance changes when schedule consistency drops."
      ],
      "sideEffectsSerious": [
        "Rapidly escalating symptoms after dose changes.",
        "Severe dehydration, confusion, or inability to maintain intake.",
        "Allergic reactions with breathing difficulty or swelling."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for L-Carnitine often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lc425",
    "title": "LC425",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC425 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LC425 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For LC425, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LC425 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "LC425 outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact LC425 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LC425 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC425 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC425: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC425",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC425: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC425",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC425: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LC425",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "LC425 is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "LC425 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact LC425 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for LC425 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lc500",
    "title": "LC500",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC500 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LC500 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For LC500, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LC500 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "LC500 outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact LC500 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LC500 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC500 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC500: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC500",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC500: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC500: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LC500",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "LC500 is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "LC500 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact LC500 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for LC500 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lc526",
    "title": "LC526",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC526 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For LC526, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For LC526, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LC526 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "LC526 outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact LC526 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LC526 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC526 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC526: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC526",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC526: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC526",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC526: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LC526",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "LC526 is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "LC526 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact LC526 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for LC526 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lc553",
    "title": "LC553",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC553 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For LC553, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "LC553 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LC553 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "LC553 outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact LC553 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LC553 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC553 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC553: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC553",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC553: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC553",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC553: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LC553",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "LC553 is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "LC553 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact LC553 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for LC553 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "letrozole",
    "title": "Letrozole",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Letrozole guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Letrozole is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With Letrozole, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Letrozole and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Letrozole users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Letrozole timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Letrozole appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Letrozole: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Letrozole",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Letrozole: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Letrozole",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Letrozole: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Letrozole",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Letrozole is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Letrozole should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Letrozole timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Letrozole often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lgd-4033-ligandrol",
    "title": "LGD-4033(Ligandrol)",
    "aliases": [
      "LGD-4033(Ligandrol)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LGD-4033(Ligandrol) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LGD-4033 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "LGD-4033 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LGD-4033 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most LGD-4033 users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact LGD-4033 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LGD-4033 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LGD-4033 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LGD-4033(Ligandrol): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LGD-4033",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LGD-4033(Ligandrol): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LGD-4033",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LGD-4033(Ligandrol): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LGD-4033",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "LGD-4033 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "LGD-4033 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact LGD-4033 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for LGD-4033 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lipo-c-120mg",
    "title": "Lipo-C 120mg",
    "aliases": [
      "Lipo-C 120mg"
    ],
    "category": "Injectable Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Lipo-C 120mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Lipo-C tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Lipo-C decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Lipo-C and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Lipo-C outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Lipo-C timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Lipo-C appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lipo-C 120mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lipo-C%20120mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lipo-C 120mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lipo-C%20120mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lipo-C 120mg: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Lipo-C%20120mg",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Lipo-C",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Lipo-C is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Lipo-C should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Lipo-C timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Lipo-C often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lipo-c-216mg",
    "title": "Lipo-C 216mg",
    "aliases": [
      "Lipo-C 216mg"
    ],
    "category": "Injectable Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Lipo-C 216mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Lipo-C tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Lipo-C, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Lipo-C and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Lipo-C outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Lipo-C timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Lipo-C appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lipo-C 216mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lipo-C%20216mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lipo-C 216mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lipo-C%20216mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lipo-C 216mg: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Lipo-C%20216mg",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Lipo-C",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Lipo-C is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Lipo-C should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Lipo-C timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Lipo-C often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "liraglutide",
    "title": "Liraglutide",
    "aliases": [
      "Victoza",
      "Saxenda"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Liraglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Liraglutide is a daily discipline game. The value is in repetition: same timing strategy, clean injection-site rotation, and symptom notes that do not blur into generic felt off entries.",
    "dosingSection": {
      "overview": "For Liraglutide, protocol moves are safer when escalation is tied to documented tolerance windows. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Liraglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Liraglutide pacing usually depends on daily-tolerance consistency rather than calendar pressure to increase. [C1]",
        "People often improve adherence by pairing administration with a fixed daily routine and meal plan. [C2]",
        "GI trend logs over consecutive days are commonly used before any escalation decision. [C3]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C2]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C3]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C4]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Liraglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Liraglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Liraglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Liraglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Liraglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Liraglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Liraglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Liraglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Liraglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Liraglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Liraglutide",
    "subtitle": "Daily GLP-1 protocol guide centered on adherence and site rotation.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Liraglutide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Liraglutide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Liraglutide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Liraglutide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lixisenatide",
    "title": "Lixisenatide",
    "aliases": [
      "Adlyxin",
      "Lyxumia"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Lixisenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "With lixisenatide, meal timing and symptom timing can overlap fast. This page helps you separate drug effect from meal context so follow-up conversations stay concrete.",
    "dosingSection": {
      "overview": "Lixisenatide should be reviewed over structured intervals, not single difficult days. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Lixisenatide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Lixisenatide protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C4]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C4]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C1]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Lixisenatide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Lixisenatide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lixisenatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Lixisenatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lixisenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lixisenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lixisenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lixisenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Lixisenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lixisenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Lixisenatide",
    "subtitle": "Shorter-acting GLP-1 daily guide with meal-timing awareness.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Lixisenatide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Lixisenatide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Lixisenatide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Lixisenatide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ll37",
    "title": "LL37",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LL37 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For LL37, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "LL37 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LL37 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "LL37 is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log LL37 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "LL37 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for LL37 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LL37: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LL37",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LL37: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LL37",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LL37: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LL37",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "LL37 is often approached as investigational support with variable evidence depth and variable product quality.",
      "LL37 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "LL37 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log LL37 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for LL37 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "lmx",
    "title": "LMX",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LMX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For LMX, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "LMX requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for LMX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "LMX outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact LMX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "LMX may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LMX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LMX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LMX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LMX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LMX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LMX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "LMX",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "LMX is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "LMX should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact LMX timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for LMX often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "magnesium",
    "title": "Magnesium",
    "aliases": [
      "Mg"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Magnesium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Magnesium works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Magnesium decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Magnesium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Magnesium, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Magnesium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Magnesium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Magnesium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Magnesium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Magnesium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Magnesium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Magnesium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Magnesium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Magnesium is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Magnesium should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Magnesium timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Magnesium often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "manganese",
    "title": "Manganese",
    "aliases": [
      "Mn"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Manganese guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Manganese works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Manganese should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Manganese schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Manganese, real-world dosing usually works best when baseline status is measured before aggressive correction. [C3]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C1]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C2]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C1]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C2]",
        "Re-check objective markers before extending high-intensity phases. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Manganese timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Manganese, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Manganese: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Manganese-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Manganese: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Manganese",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Manganese: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Manganese+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Manganese",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Manganese is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Manganese should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Manganese timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Manganese often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mast-blend-200mg",
    "title": "MAST Blend 200mg",
    "aliases": [
      "MAST Blend 200mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MAST Blend 200mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For MAST Blend, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For MAST Blend, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Treat MAST Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "MAST Blend outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact MAST Blend timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "MAST Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MAST Blend appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MAST Blend 200mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MAST%20Blend%20200mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MAST Blend 200mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MAST%20Blend%20200mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MAST Blend 200mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MAST Blend",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "MAST Blend is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "MAST Blend should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact MAST Blend timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for MAST Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mast-e-de",
    "title": "Mast E(DE)",
    "aliases": [
      "Mast E(DE)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mast E(DE) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Mast E belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Mast E should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Mast E and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Mast E outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Mast E timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Mast E may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Mast E appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mast E(DE): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mast%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mast E(DE): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mast%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mast E(DE): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Mast E",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Mast E is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Mast E should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Mast E timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Mast E often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mast-p-dp",
    "title": "Mast P(DP)",
    "aliases": [
      "Mast P(DP)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mast P(DP) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Mast P, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Mast P should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Mast P and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Mast P outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Mast P timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Mast P may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Mast P appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mast P(DP): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mast%20P",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mast P(DP): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mast%20P",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mast P(DP): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Mast P",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Mast P is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Mast P should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Mast P timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Mast P often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mazdutide",
    "title": "Mazdutide",
    "aliases": [
      "IBI362"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mazdutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Mazdutide discussions improve when progression is documented in small, interpretable steps rather than broad felt better summaries.",
    "dosingSection": {
      "overview": "Mazdutide should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Mazdutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Mazdutide protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C4]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C4]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C1]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Mazdutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Mazdutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Mazdutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mazdutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Mazdutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mazdutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Mazdutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mazdutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mazdutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Mazdutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mazdutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Mazdutide",
    "subtitle": "Mazdutide investigational profile with careful progression tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Mazdutide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Mazdutide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Mazdutide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Mazdutide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "melanotan-2",
    "title": "Melanotan II",
    "aliases": [
      "MT2"
    ],
    "category": "Other Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Melanotan II guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Melanotan II conversations should start with tolerability and risk, not cosmetic outcomes. This guide prioritizes side-effect surveillance and escalation thresholds.",
    "dosingSection": {
      "overview": "Melanotan II should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Melanotan II and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Melanotan II is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C4]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C4]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Melanotan II timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Melanotan II may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Melanotan II versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Melanotan II: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Melanotan%20II",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Melanotan II: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Melanotan%20II",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Melanotan II: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Melanotan%20II",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Melanotan II: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Melanotan%20II+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Melanotan II",
    "subtitle": "Melanotan II context with side-effect-first logging approach.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Melanotan II is often approached as investigational support with variable evidence depth and variable product quality.",
      "Melanotan II is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Melanotan II should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Melanotan II timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Melanotan II often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "melatonin",
    "title": "Melatonin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Melatonin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Melatonin looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Melatonin decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Melatonin schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Melatonin, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Melatonin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Melatonin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Melatonin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Melatonin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Melatonin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Melatonin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Melatonin: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Melatonin",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Melatonin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound",
        "Vitamin",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "support",
    "useCases": [
      "Melatonin is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Melatonin should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Log Melatonin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Melatonin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ment-trestolone-acetate",
    "title": "MENT (Trestolone acetate)",
    "aliases": [
      "MENT (Trestolone acetate)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MENT (Trestolone acetate) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For MENT, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "MENT should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MENT and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "MENT outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact MENT timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "MENT may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MENT appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MENT (Trestolone acetate): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MENT",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MENT (Trestolone acetate): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MENT",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MENT (Trestolone acetate): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MENT",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "MENT is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "MENT should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact MENT timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for MENT often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "metformin",
    "title": "Metformin",
    "aliases": [
      "Glucophage",
      "Glumetza"
    ],
    "category": "Metformin",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Metformin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Metformin is simple to prescribe but easy to log badly. Cleaner meal-context and GI timing notes make dose-tolerance decisions much safer.",
    "dosingSection": {
      "overview": "With Metformin, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Metformin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Metformin tolerance is often improved when doses stay tied to meals and increases are spread out over review windows. [C2]",
        "GI pattern logs in the first month are frequently the deciding factor for pacing or formulation changes. [C3]",
        "Daily routine consistency usually matters more than frequent short-term dose edits. [C4]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C4]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Metformin timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Metformin appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Metformin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Metformin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Metformin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Metformin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Metformin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Metformin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Metformin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Metformin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Metformin",
    "subtitle": "Metformin daily routine guide with meal and GI pattern clarity.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Metformin is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Metformin trend quality improves when timing, meal context, and tolerance logs are kept consistent.",
        "Adjustment pace should follow sustained symptom patterns rather than short-term fluctuations.",
        "Protocol review should prioritize tolerability and objective metabolic goals together."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Metformin timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Metformin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "methenolone-acetate-primobolan",
    "title": "Methenolone Acetate(Primobolan)",
    "aliases": [
      "Methenolone Acetate(Primobolan)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methenolone Acetate(Primobolan) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Methenolone Acetate, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Methenolone Acetate, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Methenolone Acetate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Methenolone Acetate users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Methenolone Acetate timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Methenolone Acetate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methenolone Acetate appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methenolone Acetate(Primobolan): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methenolone%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methenolone Acetate(Primobolan): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methenolone%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methenolone Acetate(Primobolan): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Methenolone Acetate",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Methenolone Acetate is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Methenolone Acetate should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Methenolone Acetate timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Methenolone Acetate often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "methylene-blue",
    "title": "Methylene Blue",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methylene Blue guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Methylene Blue belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Methylene Blue, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Methylene Blue and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Methylene Blue users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Methylene Blue timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Methylene Blue may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methylene Blue appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methylene Blue: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methylene%20Blue",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methylene Blue: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methylene%20Blue",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methylene Blue: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Methylene Blue",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Methylene Blue is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Methylene Blue should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Methylene Blue timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Methylene Blue often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "methylstenbolone",
    "title": "Methylstenbolone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methylstenbolone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Methylstenbolone, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Methylstenbolone requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Methylstenbolone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Methylstenbolone users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Methylstenbolone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Methylstenbolone may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methylstenbolone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methylstenbolone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methylstenbolone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methylstenbolone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methylstenbolone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methylstenbolone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Methylstenbolone",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Methylstenbolone is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Methylstenbolone should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Methylstenbolone timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Methylstenbolone often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "metribolone",
    "title": "Metribolone",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Metribolone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Metribolone should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Metribolone requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Metribolone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Metribolone outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Metribolone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Metribolone may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Metribolone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Metribolone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Metribolone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Metribolone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Metribolone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Metribolone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Metribolone",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Metribolone is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Metribolone should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Metribolone timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Metribolone often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mgf",
    "title": "MGF",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MGF guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MGF should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "MGF requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MGF and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "MGF is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log MGF timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "MGF may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for MGF versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MGF: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MGF",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MGF: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MGF",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MGF: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MGF",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "MGF is often approached as investigational support with variable evidence depth and variable product quality.",
      "MGF is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "MGF should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log MGF timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for MGF often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mic",
    "title": "MIC Injection",
    "aliases": [
      "Lipotropic Injection",
      "Lipo-B"
    ],
    "category": "Weight Loss Blend",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "MIC Injection guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "MIC blends are often treated as generic fat-loss shots. This page keeps the log specific: blend context, schedule, and realistic outcome windows.",
    "dosingSection": {
      "overview": "For MIC Injection, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MIC Injection and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "MIC Injection outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C4]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C4]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact MIC Injection timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MIC Injection appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MIC Injection: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:MIC%20Injection&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MIC Injection: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=MIC%20Injection",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MIC Injection: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MIC%20Injection",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "MIC Injection: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MIC%20Injection+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "MIC Injection",
    "subtitle": "MIC blend workflow guide with composition-aware tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound",
        "Supportive"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "MIC Injection is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "MIC Injection should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact MIC Injection timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for MIC Injection often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "minoxidil",
    "title": "Minoxidil",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Minoxidil guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Treat Minoxidil as a consistency challenge: same routine, same markers, fewer assumptions. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Minoxidil protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Minoxidil and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Minoxidil users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Minoxidil timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Minoxidil appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Minoxidil: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Minoxidil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Minoxidil: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Minoxidil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Minoxidil: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Minoxidil",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Minoxidil is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Minoxidil should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Minoxidil timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Minoxidil often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mk-677-ibutamoren",
    "title": "MK-677(Ibutamoren)",
    "aliases": [
      "MK-677(Ibutamoren)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MK-677(Ibutamoren) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MK-677 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "MK-677 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MK-677 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most MK-677 users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact MK-677 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "MK-677 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MK-677 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MK-677(Ibutamoren): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MK-677",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MK-677(Ibutamoren): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MK-677",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MK-677(Ibutamoren): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MK-677",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "MK-677 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "MK-677 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact MK-677 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for MK-677 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "molybdenum",
    "title": "Molybdenum",
    "aliases": [
      "Mo"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Molybdenum guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Molybdenum works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Molybdenum decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Molybdenum schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Molybdenum, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Molybdenum timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Molybdenum, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Molybdenum: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Molybdenum-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Molybdenum: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Molybdenum",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Molybdenum: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Molybdenum+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Molybdenum",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Molybdenum is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Molybdenum should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Molybdenum timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Molybdenum often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mots-c",
    "title": "MOTS-C",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MOTS-C guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MOTS-c is frequently discussed in performance circles. This guide keeps expectations grounded and pushes for trend windows long enough to mean something.",
    "dosingSection": {
      "overview": "MOTS-C requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MOTS-C and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "MOTS-C is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log MOTS-C timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "MOTS-C may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for MOTS-C versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MOTS-C: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-C",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MOTS-C: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MOTS-C",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MOTS-C: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MOTS-C",
    "subtitle": "MOTS-c metabolic-support context with realistic trend windows.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "MOTS-C is often approached as investigational support with variable evidence depth and variable product quality.",
      "MOTS-C is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "MOTS-C should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log MOTS-C timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for MOTS-C often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mt-1",
    "title": "MT-1",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MT-1 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For MT-1, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "MT-1 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MT-1 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "MT-1 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log MT-1 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "MT-1 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for MT-1 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MT-1: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MT-1",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MT-1: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MT-1",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MT-1: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MT-1",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "MT-1 is often approached as investigational support with variable evidence depth and variable product quality.",
      "MT-1 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "MT-1 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log MT-1 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for MT-1 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "mt-2",
    "title": "MT-2",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MT-2 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MT-2 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "MT-2 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for MT-2 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "MT-2 is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log MT-2 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "MT-2 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for MT-2 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MT-2: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MT-2",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MT-2: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MT-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MT-2: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "MT-2",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "MT-2 is often approached as investigational support with variable evidence depth and variable product quality.",
      "MT-2 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "MT-2 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log MT-2 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for MT-2 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "n-acetyl-epitalon-amidate",
    "title": "N-Acetyl Epitalon Amidate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "N-Acetyl Epitalon Amidate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "N-Acetyl Epitalon Amidate belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For N-Acetyl Epitalon Amidate, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for N-Acetyl Epitalon Amidate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "N-Acetyl Epitalon Amidate is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log N-Acetyl Epitalon Amidate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "N-Acetyl Epitalon Amidate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for N-Acetyl Epitalon Amidate versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "N-Acetyl Epitalon Amidate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=N-Acetyl%20Epitalon%20Amidate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "N-Acetyl Epitalon Amidate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=N-Acetyl%20Epitalon%20Amidate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "N-Acetyl Epitalon Amidate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "N-Acetyl Epitalon Amidate",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "N-Acetyl Epitalon Amidate is often approached as investigational support with variable evidence depth and variable product quality.",
      "N-Acetyl Epitalon Amidate is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "N-Acetyl Epitalon Amidate should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log N-Acetyl Epitalon Amidate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for N-Acetyl Epitalon Amidate often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "nad-plus",
    "title": "NAD+",
    "aliases": [
      "Nicotinamide Adenine Dinucleotide",
      "NAD"
    ],
    "category": "Coenzyme",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "NAD+ guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "NAD+ experiences are highly rate-sensitive for many users. This guide helps you log administration pace and symptom response in a way that supports safer conversations.",
    "dosingSection": {
      "overview": "NAD+ decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for NAD+ and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "NAD+ is usually handled with conservative adjustments and scheduled trend reviews. [C1]",
        "Keeping one-variable changes per review window is a common tactic to protect interpretation quality. [C2]",
        "Consistent logging windows are typically more useful than high-volume unscheduled notes. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C4]"
      ]
    },
    "trackingSignals": [
      "Document exact NAD+ timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is NAD+ appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NAD+: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:NAD%2B&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NAD+: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=NAD%2B",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NAD+: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NAD%2B",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "NAD+: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NAD%2B+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "NAD+",
    "subtitle": "NAD+ support context with administration-rate awareness.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "NAD+ should be framed as a targeted support tool with explicit goals and an exit plan.",
      "The protocol should be reviewed against objective logs rather than day-to-day mood shifts.",
      "Most users benefit from conservative pacing and early review when side effects cluster."
    ],
    "candidateProfile": [
      "Users with a clear reason for use and clinician oversight for higher-risk decisions.",
      "People who can keep objective logs and review them on a fixed schedule.",
      "Patients ready to de-escalate when risk rises faster than benefit."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI or appetite shifts during early adaptation windows.",
        "Mild headache, fatigue, or day-to-day symptom variability.",
        "Transient tolerance changes when schedule consistency drops."
      ],
      "serious": [
        "Rapidly escalating symptoms after dose changes.",
        "Severe dehydration, confusion, or inability to maintain intake.",
        "Allergic reactions with breathing difficulty or swelling."
      ]
    },
    "regulatoryContext": {
      "classification": "off_label_context",
      "plainLanguageStatus": "Supportive Therapy",
      "legalNotice": "Off-label or limited-label context can vary by clinician judgment and region; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "NAD+ should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact NAD+ timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with a clear reason for use and clinician oversight for higher-risk decisions.",
        "People who can keep objective logs and review them on a fixed schedule.",
        "Patients ready to de-escalate when risk rises faster than benefit.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI or appetite shifts during early adaptation windows.",
        "Mild headache, fatigue, or day-to-day symptom variability.",
        "Transient tolerance changes when schedule consistency drops."
      ],
      "sideEffectsSerious": [
        "Rapidly escalating symptoms after dose changes.",
        "Severe dehydration, confusion, or inability to maintain intake.",
        "Allergic reactions with breathing difficulty or swelling."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for NAD+ often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "nandromix-300mg",
    "title": "NANDROMIX 300mg",
    "aliases": [
      "NANDROMIX 300mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "NANDROMIX 300mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "NANDROMIX should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "NANDROMIX should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for NANDROMIX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "NANDROMIX outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact NANDROMIX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "NANDROMIX may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is NANDROMIX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NANDROMIX 300mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NANDROMIX%20300mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NANDROMIX 300mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NANDROMIX%20300mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NANDROMIX 300mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "NANDROMIX",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "NANDROMIX is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "NANDROMIX should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact NANDROMIX timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for NANDROMIX often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "npp",
    "title": "NPP",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "NPP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For NPP, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "NPP should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for NPP and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "NPP outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact NPP timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "NPP may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is NPP appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NPP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NPP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NPP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NPP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NPP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "NPP",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "NPP is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "NPP should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact NPP timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for NPP often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "orforglipron",
    "title": "Orforglipron",
    "aliases": [
      "LY3502970"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Orforglipron guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Orforglipron discussions usually fail when people treat trial headlines like finished clinical guidance. This guide keeps the focus on uncertainty, tolerability, and disciplined monitoring.",
    "dosingSection": {
      "overview": "Orforglipron requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Orforglipron so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Orforglipron protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C4]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C4]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C1]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Orforglipron dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Orforglipron may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Orforglipron titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Orforglipron: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Orforglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Orforglipron: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Orforglipron",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Orforglipron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Orforglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Orforglipron: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Orforglipron+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Orforglipron",
    "subtitle": "Oral investigational incretin profile with cautious expectation setting.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "GLP-1/GIP",
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Orforglipron is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Orforglipron is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Orforglipron dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Orforglipron often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ostarine-mk-2866",
    "title": "Ostarine / MK-2866",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ostarine / MK-2866 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Ostarine / MK-2866, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Ostarine / MK-2866 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Ostarine / MK-2866 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Ostarine / MK-2866 users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Ostarine / MK-2866 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Ostarine / MK-2866 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Ostarine / MK-2866 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ostarine / MK-2866: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ostarine%20%2F%20MK-2866",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ostarine / MK-2866: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ostarine%20%2F%20MK-2866",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ostarine / MK-2866: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Ostarine / MK-2866",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Ostarine / MK-2866 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Ostarine / MK-2866 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Ostarine / MK-2866 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Ostarine / MK-2866 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "oxytocin-acetate",
    "title": "Oxytocin Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Oxytocin Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Oxytocin Acetate should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Oxytocin Acetate, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Oxytocin Acetate and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Oxytocin Acetate plans are commonly anchored to regular lab checkpoints rather than symptom-only adjustments. [C2]",
        "Real-world teams often avoid simultaneous multi-compound changes so response remains interpretable. [C3]",
        "Dose timing consistency is a major determinant of stable trend interpretation. [C1]"
      ],
      "escalationBoundaries": [
        "Stop ad-hoc escalation when lab trends or blood-pressure/symptom signals become unstable. [C3]",
        "Avoid adding new hormone-active agents in the same window as dose escalation. [C1]",
        "Escalate only after objective review confirms benefit exceeds current risk. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Oxytocin Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Oxytocin Acetate may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Oxytocin Acetate versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Oxytocin Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Oxytocin%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Oxytocin Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Oxytocin%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Oxytocin Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Oxytocin Acetate",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Hormone",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Oxytocin Acetate is typically discussed for endocrine goals that require baseline labs and regular follow-up.",
      "Benefit and risk are driven by how well labs, symptoms, and timing are tracked together.",
      "Dose changes usually belong inside a supervised plan rather than ad-hoc cycle edits."
    ],
    "candidateProfile": [
      "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
      "People able to complete repeat labs and clinical follow-up on schedule.",
      "Users who can avoid stacking multiple endocrine-active compounds at the same time."
    ],
    "avoidanceFlags": [
      "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
      "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "serious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Oxytocin Acetate should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Log Oxytocin Acetate timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
        "People able to complete repeat labs and clinical follow-up on schedule.",
        "Users who can avoid stacking multiple endocrine-active compounds at the same time.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
        "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "sideEffectsSerious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Oxytocin Acetate often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "p21",
    "title": "P21",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "P21 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For P21, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "P21 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for P21 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "P21 is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log P21 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "P21 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for P21 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "P21: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=P21",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "P21: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=P21",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "P21: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "P21",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "P21 is often approached as investigational support with variable evidence depth and variable product quality.",
      "P21 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "P21 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log P21 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for P21 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "pe-22-28",
    "title": "PE 22-28",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PE 22-28 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "PE 22-28 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "PE 22-28 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for PE 22-28 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "PE 22-28 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log PE 22-28 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "PE 22-28 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for PE 22-28 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PE 22-28: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PE%2022-28",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PE 22-28: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PE%2022-28",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PE 22-28: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "PE 22-28",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "PE 22-28 is often approached as investigational support with variable evidence depth and variable product quality.",
      "PE 22-28 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "PE 22-28 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log PE 22-28 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for PE 22-28 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "peg-mgf",
    "title": "PEG MGF",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PEG MGF guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "PEG MGF belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "PEG MGF should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for PEG MGF and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "PEG MGF is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log PEG MGF timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "PEG MGF may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for PEG MGF versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PEG MGF: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PEG%20MGF",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PEG MGF: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PEG%20MGF",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PEG MGF: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "PEG MGF",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "PEG MGF is often approached as investigational support with variable evidence depth and variable product quality.",
      "PEG MGF is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "PEG MGF should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log PEG MGF timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for PEG MGF often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "phosphorus",
    "title": "Phosphorus",
    "aliases": [
      "P"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Phosphorus guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Phosphorus looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Phosphorus decisions should be tied to objective follow-up markers whenever possible. [C1]",
      "protocolPatterns": [
        "Keep Phosphorus schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Phosphorus, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Phosphorus timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Phosphorus, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Phosphorus: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Phosphorus-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Phosphorus: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Phosphorus",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Phosphorus: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Phosphorus+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Phosphorus",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Phosphorus is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Phosphorus should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Phosphorus timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Phosphorus often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "pinealon",
    "title": "Pinealon",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Pinealon guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Pinealon belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Pinealon requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Pinealon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Pinealon is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Pinealon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Pinealon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Pinealon versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Pinealon: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Pinealon",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Pinealon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Pinealon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Pinealon: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Pinealon",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Pinealon is often approached as investigational support with variable evidence depth and variable product quality.",
      "Pinealon is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Pinealon should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Pinealon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Pinealon often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "pnc-27",
    "title": "PNC 27",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PNC 27 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For PNC 27, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "PNC 27 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for PNC 27 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "PNC 27 is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log PNC 27 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "PNC 27 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for PNC 27 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PNC 27: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PNC%2027",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PNC 27: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PNC%2027",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PNC 27: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "PNC 27",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "PNC 27 is often approached as investigational support with variable evidence depth and variable product quality.",
      "PNC 27 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "PNC 27 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log PNC 27 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for PNC 27 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "potassium",
    "title": "Potassium",
    "aliases": [
      "K"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Potassium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Potassium works best as a steady support protocol with measured check-ins rather than short reactive cycles. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Potassium should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Potassium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Potassium, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Potassium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Potassium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Potassium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Potassium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Potassium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Potassium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Potassium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Potassium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Potassium is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Potassium should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Potassium timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Potassium often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "prednisone",
    "title": "Prednisone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Prednisone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Prednisone tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Prednisone protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Prednisone and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Prednisone users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Prednisone timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Prednisone appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Prednisone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Prednisone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Prednisone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Prednisone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Prednisone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Prednisone",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Prednisone is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Prednisone should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Prednisone timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Prednisone often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "primobolan-e",
    "title": "Primobolan E",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Primobolan E guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Primobolan E belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Primobolan E requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Primobolan E and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Primobolan E outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Primobolan E timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Primobolan E may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Primobolan E appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Primobolan E: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Primobolan%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Primobolan E: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Primobolan%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Primobolan E: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Primobolan E",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Primobolan E is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Primobolan E should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Primobolan E timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Primobolan E often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "proviron",
    "title": "Proviron",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Proviron guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Proviron belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Proviron should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Proviron and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Proviron users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Proviron timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Proviron may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Proviron appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Proviron: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Proviron",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Proviron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Proviron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Proviron: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Proviron",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Proviron is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Proviron should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Proviron timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Proviron often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "pt-141",
    "title": "PT-141 (Bremelanotide)",
    "aliases": [
      "Vyleesi",
      "PT-141",
      "PT-141 (Bremelanotide)"
    ],
    "category": "Other Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "PT-141 (Bremelanotide) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "PT-141 is typically discussed as-needed, which makes logs messy fast. This guide helps you structure timing, trigger context, and response windows.",
    "dosingSection": {
      "overview": "PT-141 protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for PT-141 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "PT-141 is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C4]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C4]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log PT-141 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for PT-141 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PT-141 (Bremelanotide): FDA/openFDA labeling and safety records",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PT-141 (Bremelanotide): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=PT-141",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PT-141 (Bremelanotide): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PT-141",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "PT-141 (Bremelanotide): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PT-141+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "PT-141",
    "subtitle": "PT-141 on-demand context with timing and response structure.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach",
    "useCases": [
      "PT-141 is often approached as investigational support with variable evidence depth and variable product quality.",
      "PT-141 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "PT-141 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log PT-141 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for PT-141 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "rad140",
    "title": "RAD140",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RAD140 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RAD140 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "RAD140 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for RAD140 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most RAD140 users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact RAD140 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "RAD140 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RAD140 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RAD140: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RAD140",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RAD140: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RAD140",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RAD140: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "RAD140",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "RAD140 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "RAD140 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact RAD140 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for RAD140 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "retatrutide",
    "title": "Retatrutide",
    "aliases": [
      "LY3437943"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Retatrutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Retatrutide conversation should start with uncertainty, not hype. Treat it like a high-variance investigational signal: conservative expectations, documented side effects, and zero self-directed escalation.",
    "dosingSection": {
      "overview": "Retatrutide requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Retatrutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Retatrutide protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C4]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C4]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C1]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Retatrutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Retatrutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Retatrutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Retatrutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Retatrutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Retatrutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Retatrutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Retatrutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Retatrutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Retatrutide",
    "subtitle": "Investigational triple-agonist context with strict safety framing.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Retatrutide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Retatrutide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Retatrutide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Retatrutide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "retatrutide-5mg-plus-cagrilintide-5mg-blend",
    "title": "Retatrutide 5mg+Cagrilintide 5mg Blend",
    "aliases": [
      "Retatrutide 5mg+Cagrilintide 5mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Retatrutide 5mg+Cagrilintide 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Retatrutide + Cagrilintide Blend belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Retatrutide + Cagrilintide Blend should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Retatrutide + Cagrilintide Blend so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Retatrutide + Cagrilintide Blend protocols are paced slowly, with escalation only after multi-week tolerance review. [C2]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C3]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C1]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C3]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C1]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C2]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Retatrutide + Cagrilintide Blend dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Retatrutide + Cagrilintide Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Retatrutide + Cagrilintide Blend titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Retatrutide%205mg%2BCagrilintide%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide%205mg%2BCagrilintide%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Retatrutide + Cagrilintide Blend",
    "subtitle": "Retatrutide + Cagrilintide blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Retatrutide",
        "amount": "5mg"
      },
      {
        "name": "Cagrilintide",
        "amount": "5mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Retatrutide + Cagrilintide Blend is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Retatrutide + Cagrilintide Blend is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Retatrutide + Cagrilintide Blend dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Retatrutide + Cagrilintide Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ripex",
    "title": "RIPEX",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RIPEX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RIPEX belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For RIPEX, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for RIPEX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "RIPEX outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact RIPEX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "RIPEX may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RIPEX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RIPEX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RIPEX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RIPEX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RIPEX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RIPEX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "RIPEX",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "RIPEX is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "RIPEX should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact RIPEX timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for RIPEX often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "rp226",
    "title": "RP226",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RP226 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RP226 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "RP226 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for RP226 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "RP226 outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact RP226 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "RP226 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RP226 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RP226: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RP226",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RP226: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RP226",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RP226: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "RP226",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "RP226 is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "RP226 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact RP226 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for RP226 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "salbutamol",
    "title": "SALBUTAMOL",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SALBUTAMOL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SALBUTAMOL belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "SALBUTAMOL requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SALBUTAMOL and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most SALBUTAMOL users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact SALBUTAMOL timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SALBUTAMOL may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SALBUTAMOL appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SALBUTAMOL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SALBUTAMOL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SALBUTAMOL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SALBUTAMOL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SALBUTAMOL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SALBUTAMOL",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "SALBUTAMOL is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "SALBUTAMOL should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact SALBUTAMOL timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for SALBUTAMOL often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "selank",
    "title": "Selank",
    "aliases": [
      "Tuftsin Analog"
    ],
    "category": "Nootropic Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Selank guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Selank logs tend to over-index on subjective mood snapshots. This guide pushes a more useful approach: day-function markers, consistency, and timing clarity.",
    "dosingSection": {
      "overview": "Selank requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Selank and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Selank is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C4]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C4]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Selank timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Selank may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Selank versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selank: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Selank",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selank: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Selank",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selank: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Selank",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Selank: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selank+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Selank",
    "subtitle": "Nootropic peptide context with day-function tracking cues.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Selank is often approached as investigational support with variable evidence depth and variable product quality.",
      "Selank is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Selank should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Selank timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Selank often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "selank-10mg-plus-semax-10mg-blend",
    "title": "Selank 10mg + Semax 10mg Blend",
    "aliases": [
      "Selank 10mg + Semax 10mg Blend"
    ],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Selank 10mg + Semax 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Selank + Semax Blend should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Selank + Semax Blend, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Treat Selank + Semax Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "Selank + Semax Blend is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Blend protocols are typically interpreted component-by-component so one reaction does not misclassify the entire stack. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log Selank + Semax Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Selank + Semax Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Selank + Semax Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selank 10mg + Semax 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selank%2010mg%20%2B%20Semax%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selank 10mg + Semax 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Selank%2010mg%20%2B%20Semax%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selank 10mg + Semax 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Selank + Semax Blend",
    "subtitle": "Selank + Semax blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Selank",
        "amount": "10mg"
      },
      {
        "name": "Semax",
        "amount": "10mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Selank + Semax Blend is often approached as investigational support with variable evidence depth and variable product quality.",
      "Selank + Semax Blend is a blend, so interpretation should stay component-aware instead of treating every response as one signal.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Selank + Semax Blend should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Selank + Semax Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Selank + Semax Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "selenium",
    "title": "Selenium",
    "aliases": [
      "Se"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Selenium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Selenium looks simple, but better results usually come from routine, timing consistency, and objective follow-up. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "Selenium should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Selenium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Selenium, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Selenium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Selenium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selenium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selenium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Selenium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selenium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selenium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Selenium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Selenium is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Selenium should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Selenium timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Selenium often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "semaglutide",
    "title": "Semaglutide",
    "aliases": [
      "Ozempic",
      "Wegovy",
      "Rybelsus"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Semaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Semaglutide works best when the weekly rhythm is boringly consistent. This guide focuses on the real-world cadence: dose day, appetite curve, GI tolerance windows, and clean notes your clinician can act on.",
    "dosingSection": {
      "overview": "For Semaglutide, protocol moves are safer when escalation is tied to documented tolerance windows. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Semaglutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Semaglutide protocols are commonly reviewed week-by-week, with step-ups only after stable tolerance windows. [C1]",
        "In practice, dose-day meal size and hydration strategy are often adjusted before changing the dose itself. [C2]",
        "Appetite-return timing, GI score trends, and hydration logs are the highest-yield inputs at titration visits. [C3]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C2]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C3]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C4]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Semaglutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Semaglutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Semaglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Semaglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Semaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Semaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Semaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Semaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Semaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Semaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Semaglutide",
    "subtitle": "Weekly GLP-1 anchor protocol with appetite and GI trend tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Semaglutide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Semaglutide trend review is strongest when appetite-return, hydration, and GI tolerance are logged in a consistent weekly rhythm.",
        "Escalation timing should follow tolerance stability and clinician review, not calendar pressure.",
        "Single-variable adjustments protect signal quality during protocol review."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Semaglutide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Semaglutide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "semax",
    "title": "Semax",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Semax guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Semax discussions improve when cognitive claims are tied to repeatable tasks and routine windows, not one-off impressions.",
    "dosingSection": {
      "overview": "Semax requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Semax and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Semax is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C1]"
      ]
    },
    "trackingSignals": [
      "Log Semax timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Semax may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Semax versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Semax: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Semax",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Semax: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Semax",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Semax: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Semax",
    "subtitle": "Semax cognitive-support tracking guide with structured notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Semax is often approached as investigational support with variable evidence depth and variable product quality.",
      "Semax is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Semax should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Semax timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Semax often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "sermorelin",
    "title": "Sermorelin",
    "aliases": [
      "GHRH 1-29",
      "Sermorelin Acetate"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sermorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Sermorelin outcomes are hard to read without consistent nighttime routine context. This page helps keep sleep, timing, and next-day markers aligned.",
    "dosingSection": {
      "overview": "Sermorelin requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Sermorelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Sermorelin is usually paced conservatively in real-world use due to evidence and quality variability. [C1]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C2]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C3]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C2]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C3]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C4]"
      ]
    },
    "trackingSignals": [
      "Log Sermorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Sermorelin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Sermorelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sermorelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Sermorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sermorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sermorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sermorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sermorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Sermorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sermorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Sermorelin",
    "subtitle": "Sermorelin practical tracking guide for nightly protocol routines.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Sermorelin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Sermorelin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Sermorelin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Sermorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Sermorelin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "shb",
    "title": "SHB",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SHB guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SHB should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "SHB should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SHB and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "SHB outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact SHB timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SHB may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SHB appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SHB: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SHB: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SHB: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SHB",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "SHB is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "SHB should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact SHB timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for SHB often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "shr",
    "title": "SHR",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SHR guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SHR belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "SHR should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SHR and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "SHR outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact SHR timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SHR may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SHR appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SHR: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SHR",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SHR: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SHR",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SHR: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SHR",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "SHR is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "SHR should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact SHR timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for SHR often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "sildenafil-viagra",
    "title": "Sildenafil(Viagra)",
    "aliases": [
      "Sildenafil(Viagra)"
    ],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Sildenafil(Viagra) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sildenafil tracking improves fast once you define one clear objective and log against it every week. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Sildenafil protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Sildenafil and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Sildenafil users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Sildenafil timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Sildenafil appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sildenafil(Viagra): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sildenafil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sildenafil(Viagra): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sildenafil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sildenafil(Viagra): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Sildenafil",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Sildenafil is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Sildenafil should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Sildenafil timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Sildenafil often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "slu-pp-332",
    "title": "SLU-PP-332",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SLU-PP-332 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SLU-PP-332 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "SLU-PP-332 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SLU-PP-332 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most SLU-PP-332 users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact SLU-PP-332 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SLU-PP-332 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SLU-PP-332 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SLU-PP-332: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SLU-PP-332",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SLU-PP-332: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SLU-PP-332",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SLU-PP-332: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SLU-PP-332",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "SLU-PP-332 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "SLU-PP-332 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact SLU-PP-332 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for SLU-PP-332 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "slupp-332-250mcg-plus-bam15-50mcg",
    "title": "slupp-332 250mcg+BAM15 50mcg",
    "aliases": [
      "slupp-332 250mcg+BAM15 50mcg"
    ],
    "category": "Compound Blend",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "slupp-332 250mcg+BAM15 50mcg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Slupp 332 + Bam15 Blend, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Slupp 332 + Bam15 Blend, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Treat Slupp 332 + Bam15 Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "Slupp 332 + Bam15 Blend is usually handled with conservative adjustments and scheduled trend reviews. [C2]",
        "Keeping one-variable changes per review window is a common tactic to protect interpretation quality. [C3]",
        "Consistent logging windows are typically more useful than high-volume unscheduled notes. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Slupp 332 + Bam15 Blend timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Slupp 332 + Bam15 Blend may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Slupp 332 + Bam15 Blend appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "slupp-332 250mcg+BAM15 50mcg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=slupp-332%20250mcg%2BBAM15%2050mcg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "slupp-332 250mcg+BAM15 50mcg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=slupp-332%20250mcg%2BBAM15%2050mcg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "slupp-332 250mcg+BAM15 50mcg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Slupp 332 + Bam15 Blend",
    "subtitle": "Slupp 332 + Bam15 blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Slupp 332",
        "amount": "250mcg"
      },
      {
        "name": "Bam15",
        "amount": "50mcg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Slupp 332 + Bam15 Blend should be framed as a targeted support tool with explicit goals and an exit plan.",
      "The protocol should be reviewed against objective logs rather than day-to-day mood shifts.",
      "Most users benefit from conservative pacing and early review when side effects cluster."
    ],
    "candidateProfile": [
      "Users with a clear reason for use and clinician oversight for higher-risk decisions.",
      "People who can keep objective logs and review them on a fixed schedule.",
      "Patients ready to de-escalate when risk rises faster than benefit."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI or appetite shifts during early adaptation windows.",
        "Mild headache, fatigue, or day-to-day symptom variability.",
        "Transient tolerance changes when schedule consistency drops."
      ],
      "serious": [
        "Rapidly escalating symptoms after dose changes.",
        "Severe dehydration, confusion, or inability to maintain intake.",
        "Allergic reactions with breathing difficulty or swelling."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Slupp 332 + Bam15 Blend should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Slupp 332 + Bam15 Blend timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with a clear reason for use and clinician oversight for higher-risk decisions.",
        "People who can keep objective logs and review them on a fixed schedule.",
        "Patients ready to de-escalate when risk rises faster than benefit.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI or appetite shifts during early adaptation windows.",
        "Mild headache, fatigue, or day-to-day symptom variability.",
        "Transient tolerance changes when schedule consistency drops."
      ],
      "sideEffectsSerious": [
        "Rapidly escalating symptoms after dose changes.",
        "Severe dehydration, confusion, or inability to maintain intake.",
        "Allergic reactions with breathing difficulty or swelling."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Slupp 332 + Bam15 Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "snap-8",
    "title": "SNAP-8",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SNAP-8 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SNAP-8 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "SNAP-8 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SNAP-8 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "SNAP-8 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log SNAP-8 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "SNAP-8 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for SNAP-8 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SNAP-8: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SNAP-8",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SNAP-8: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SNAP-8",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SNAP-8: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SNAP-8",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "SNAP-8 is often approached as investigational support with variable evidence depth and variable product quality.",
      "SNAP-8 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "SNAP-8 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log SNAP-8 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for SNAP-8 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "sodium",
    "title": "Sodium",
    "aliases": [
      "Na"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Sodium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Sodium tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "For Sodium, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Keep Sodium schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Sodium, real-world dosing usually works best when baseline status is measured before aggressive correction. [C3]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C1]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C2]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C1]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C2]",
        "Re-check objective markers before extending high-intensity phases. [C3]"
      ]
    },
    "trackingSignals": [
      "Track Sodium timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Sodium, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sodium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/list-all/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sodium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Sodium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sodium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sodium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Sodium",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Sodium is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Sodium should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Sodium timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Sodium often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "sr9009",
    "title": "SR9009",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SR9009 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SR9009 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For SR9009, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SR9009 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most SR9009 users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact SR9009 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "SR9009 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SR9009 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SR9009: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SR9009",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SR9009: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SR9009",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SR9009: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SR9009",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "SR9009 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "SR9009 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact SR9009 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for SR9009 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "ss-31",
    "title": "SS-31",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SS-31 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SS-31 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "SS-31 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for SS-31 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "SS-31 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log SS-31 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "SS-31 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for SS-31 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SS-31: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SS-31",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SS-31: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SS-31",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SS-31: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "SS-31",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "SS-31 is often approached as investigational support with variable evidence depth and variable product quality.",
      "SS-31 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "SS-31 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log SS-31 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for SS-31 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "stanozolol-oil-base-winstrol",
    "title": "STANOZOLOL(Oil base)winstrol",
    "aliases": [
      "STANOZOLOL(Water)winstrol",
      "STANOZOLOL(Oil base)winstrol"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "STANOZOLOL(Oil base)winstrol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "STANOZOLOL winstrol belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "STANOZOLOL winstrol should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for STANOZOLOL winstrol and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "STANOZOLOL winstrol outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact STANOZOLOL winstrol timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "STANOZOLOL winstrol may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is STANOZOLOL winstrol appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "STANOZOLOL(Oil base)winstrol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=STANOZOLOLwinstrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "STANOZOLOL(Oil base)winstrol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=STANOZOLOLwinstrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "STANOZOLOL(Oil base)winstrol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "STANOZOLOL winstrol",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "STANOZOLOL winstrol is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "STANOZOLOL winstrol should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact STANOZOLOL winstrol timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for STANOZOLOL winstrol often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "superdrol",
    "title": "Superdrol",
    "aliases": [
      "Superdrol(Methyldrostanolone)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Superdrol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Superdrol, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Superdrol, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Superdrol and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Superdrol users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Superdrol timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Superdrol may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Superdrol appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Superdrol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Superdrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Superdrol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Superdrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Superdrol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Superdrol",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Superdrol is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Superdrol should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Superdrol timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Superdrol often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "supertest-450mg",
    "title": "Supertest 450mg",
    "aliases": [
      "Supertest 450mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Supertest 450mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Supertest should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Supertest requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Supertest and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Supertest outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Supertest timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Supertest may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Supertest appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Supertest 450mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Supertest%20450mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Supertest 450mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Supertest%20450mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Supertest 450mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Supertest",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Supertest is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Supertest should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Supertest timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Supertest often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "survodutide",
    "title": "Survodutide",
    "aliases": [
      "BI 456906"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Survodutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Survodutide should be handled like a high-uncertainty candidate. The right posture is conservative assumptions, explicit stop rules, and source-backed review.",
    "dosingSection": {
      "overview": "Survodutide should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Survodutide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Most Survodutide protocols are paced slowly, with escalation only after multi-week tolerance review. [C3]",
        "Many clinicians prioritize hydration and smaller meal structure around dose day to reduce avoidable GI burden. [C4]",
        "Weekly trend reviews usually outperform day-by-day reaction decisions when choosing hold vs. step-up. [C1]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C4]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C1]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C2]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Survodutide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Survodutide may have incomplete long-term safety evidence; keep expectations conservative.",
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Survodutide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Survodutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Survodutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Survodutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Survodutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Survodutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Survodutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Survodutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Survodutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Survodutide",
    "subtitle": "Investigational metabolic therapy with strong caution posture.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Survodutide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Survodutide is usually reviewed over consistent multi-week trend windows before any protocol adjustment.",
        "Tolerance, hydration, and symptom trajectory should be interpreted together rather than from a single difficult day.",
        "One variable change per review window improves safety interpretation quality."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Survodutide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Survodutide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "sustanon-250mg",
    "title": "Sustanon 250mg",
    "aliases": [
      "Sustanon 250mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sustanon 250mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sustanon belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Sustanon should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Sustanon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Sustanon outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Sustanon timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Sustanon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Sustanon appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sustanon 250mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sustanon%20250mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sustanon 250mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sustanon%20250mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sustanon 250mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Sustanon",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Sustanon is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Sustanon should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Sustanon timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Sustanon often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "sustanon-400mg",
    "title": "Sustanon 400mg",
    "aliases": [
      "Sustanon 400mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sustanon 400mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sustanon belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Sustanon should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Sustanon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Sustanon outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Sustanon timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Sustanon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Sustanon appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sustanon 400mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sustanon%20400mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sustanon 400mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sustanon%20400mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sustanon 400mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Sustanon",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Sustanon is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Sustanon should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Sustanon timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Sustanon often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "t3",
    "title": "T3",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "T3 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "T3 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For T3, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for T3 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "T3 plans are commonly anchored to regular lab checkpoints rather than symptom-only adjustments. [C2]",
        "Real-world teams often avoid simultaneous multi-compound changes so response remains interpretable. [C3]",
        "Dose timing consistency is a major determinant of stable trend interpretation. [C1]"
      ],
      "escalationBoundaries": [
        "Stop ad-hoc escalation when lab trends or blood-pressure/symptom signals become unstable. [C3]",
        "Avoid adding new hormone-active agents in the same window as dose escalation. [C1]",
        "Escalate only after objective review confirms benefit exceeds current risk. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact T3 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "T3 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is T3 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "T3: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=T3",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "T3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=T3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "T3: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "T3",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Hormone",
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "T3 is typically discussed for endocrine goals that require baseline labs and regular follow-up.",
      "Benefit and risk are driven by how well labs, symptoms, and timing are tracked together.",
      "Dose changes usually belong inside a supervised plan rather than ad-hoc cycle edits."
    ],
    "candidateProfile": [
      "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
      "People able to complete repeat labs and clinical follow-up on schedule.",
      "Users who can avoid stacking multiple endocrine-active compounds at the same time."
    ],
    "avoidanceFlags": [
      "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
      "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "serious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "T3 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact T3 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
        "People able to complete repeat labs and clinical follow-up on schedule.",
        "Users who can avoid stacking multiple endocrine-active compounds at the same time.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
        "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "sideEffectsSerious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for T3 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "t4",
    "title": "T4",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "T4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "T4 belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "T4 requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for T4 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "T4 plans are commonly anchored to regular lab checkpoints rather than symptom-only adjustments. [C1]",
        "Real-world teams often avoid simultaneous multi-compound changes so response remains interpretable. [C2]",
        "Dose timing consistency is a major determinant of stable trend interpretation. [C3]"
      ],
      "escalationBoundaries": [
        "Stop ad-hoc escalation when lab trends or blood-pressure/symptom signals become unstable. [C2]",
        "Avoid adding new hormone-active agents in the same window as dose escalation. [C3]",
        "Escalate only after objective review confirms benefit exceeds current risk. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact T4 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "T4 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is T4 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "T4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=T4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "T4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=T4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "T4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "T4",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Hormone",
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "T4 is typically discussed for endocrine goals that require baseline labs and regular follow-up.",
      "Benefit and risk are driven by how well labs, symptoms, and timing are tracked together.",
      "Dose changes usually belong inside a supervised plan rather than ad-hoc cycle edits."
    ],
    "candidateProfile": [
      "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
      "People able to complete repeat labs and clinical follow-up on schedule.",
      "Users who can avoid stacking multiple endocrine-active compounds at the same time."
    ],
    "avoidanceFlags": [
      "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
      "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "serious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "T4 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact T4 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Patients with a clear endocrine objective and baseline lab panel before protocol decisions.",
        "People able to complete repeat labs and clinical follow-up on schedule.",
        "Users who can avoid stacking multiple endocrine-active compounds at the same time.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unmonitored hormone-active stacks can produce unstable labs and misleading symptom interpretation.",
        "Cardiometabolic risk factors or thrombotic risk require tighter clinical monitoring.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Fluid shifts, mood variability, appetite changes, or sleep disturbance.",
        "Acne/oily skin, libido shifts, or cycle-related changes depending on protocol context.",
        "Injection-site irritation for injectable formulations."
      ],
      "sideEffectsSerious": [
        "Rapid blood-pressure changes, chest symptoms, neurologic symptoms, or syncope.",
        "Escalating edema, severe mood destabilization, or persistent severe headache.",
        "Thrombotic or cardiometabolic red flags requiring urgent medical review."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for T4 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tadalafil-cialis",
    "title": "Tadalafil(Cialis)",
    "aliases": [
      "Tadalafil(Cialis)"
    ],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tadalafil(Cialis) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Treat Tadalafil as a consistency challenge: same routine, same markers, fewer assumptions. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Tadalafil protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tadalafil and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Tadalafil users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Tadalafil timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tadalafil appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tadalafil(Cialis): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tadalafil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tadalafil(Cialis): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tadalafil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tadalafil(Cialis): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tadalafil",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Tadalafil is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tadalafil should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Tadalafil timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tadalafil often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tamoxifen-nolvadex",
    "title": "Tamoxifen(Nolvadex)",
    "aliases": [
      "Tamoxifen(Nolvadex)"
    ],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tamoxifen(Nolvadex) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Treat Tamoxifen as a consistency challenge: same routine, same markers, fewer assumptions. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "With Tamoxifen, consistency beats complexity. Hold one clean routine long enough to produce signal. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tamoxifen and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Tamoxifen users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Tamoxifen timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tamoxifen appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tamoxifen(Nolvadex): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tamoxifen",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tamoxifen(Nolvadex): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tamoxifen",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tamoxifen(Nolvadex): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tamoxifen",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Tamoxifen is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tamoxifen should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Tamoxifen timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tamoxifen often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tb-500",
    "title": "TB-500 (Thymosin Beta-4)",
    "aliases": [
      "Thymosin Beta-4",
      "TB-500(TB4)",
      "TB-500 (Thymosin Beta-4)"
    ],
    "category": "Healing Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TB-500 (Thymosin Beta-4) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "TB-500 is often discussed in loading and maintenance phases. If you do not segment your log by phase, you cannot tell what changed or why.",
    "dosingSection": {
      "overview": "For TB-500, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TB-500 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TB-500 is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C4]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C4]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log TB-500 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "TB-500 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for TB-500 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TB-500 (Thymosin Beta-4): Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TB-500 (Thymosin Beta-4): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=TB-500",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TB-500 (Thymosin Beta-4): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "TB-500 (Thymosin Beta-4): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TB-500+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "TB-500",
    "subtitle": "TB-500 recovery-cycle guide with phase-based monitoring.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "TB-500 is often approached as investigational support with variable evidence depth and variable product quality.",
      "TB-500 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TB-500 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log TB-500 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TB-500 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tb-500-frag",
    "title": "TB-500 FRAG",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TB-500 FRAG guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For TB-500 FRAG, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "TB-500 FRAG requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TB-500 FRAG and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TB-500 FRAG is usually paced conservatively in real-world use due to evidence and quality variability. [C3]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log TB-500 FRAG timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "TB-500 FRAG may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for TB-500 FRAG versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TB-500 FRAG: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TB-500%20FRAG",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TB-500 FRAG: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500%20FRAG",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TB-500 FRAG: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TB-500 FRAG",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "TB-500 FRAG is often approached as investigational support with variable evidence depth and variable product quality.",
      "TB-500 FRAG is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TB-500 FRAG should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log TB-500 FRAG timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TB-500 FRAG often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "telmisartan",
    "title": "Telmisartan",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Telmisartan guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Treat Telmisartan as a consistency challenge: same routine, same markers, fewer assumptions. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Telmisartan protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Telmisartan and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Telmisartan users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Telmisartan timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Telmisartan appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Telmisartan: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Telmisartan",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Telmisartan: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Telmisartan",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Telmisartan: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Telmisartan",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "coach",
    "useCases": [
      "Telmisartan is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Telmisartan should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Telmisartan timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Telmisartan often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tesamorelin",
    "title": "Tesamorelin",
    "aliases": [
      "Egrifta"
    ],
    "category": "GH Secretagogue",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tesamorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Tesamorelin is one of the few entries here with clearer clinical pathway context. Still, better outcomes come from indication-aware logging and disciplined follow-up.",
    "dosingSection": {
      "overview": "Tesamorelin protocols are easier to interpret when you avoid changing multiple variables at once. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tesamorelin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Tesamorelin is usually paced conservatively in real-world use due to evidence and quality variability. [C4]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C1]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C2]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C1]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C2]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C3]"
      ]
    },
    "trackingSignals": [
      "Log Tesamorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Tesamorelin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesamorelin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Tesamorelin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesamorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tesamorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesamorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Tesamorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesamorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Tesamorelin",
    "subtitle": "Tesamorelin guide with indication-aware safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach",
    "useCases": [
      "Tesamorelin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Tesamorelin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tesamorelin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Tesamorelin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tesamorelin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tesamorelin-11mg-plus-ipamorelin-6mg-blend",
    "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend",
    "aliases": [
      "Tesamorelin 11mg + Ipamorelin 6mg Blend"
    ],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tesamorelin 11mg + Ipamorelin 6mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tesamorelin + Ipamorelin Blend is easier to judge when your notes read like a timeline instead of scattered snapshots. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Tesamorelin + Ipamorelin Blend, stable cadence is the foundation for any useful adjustment discussion. [C1]",
      "protocolPatterns": [
        "Treat Tesamorelin + Ipamorelin Blend as a multi-signal protocol and define what each component is expected to influence. [C2]",
        "Do not add new stacked compounds mid-cycle unless you can isolate effects clearly. [C3]"
      ],
      "monitoringWindows": [
        "Log component-related outcomes separately before making blend-level conclusions. [C2]",
        "Escalate unusual reactions quickly since blend attribution is inherently less precise. [C3]"
      ],
      "realWorldPatterns": [
        "Tesamorelin + Ipamorelin Blend is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Blend protocols are typically interpreted component-by-component so one reaction does not misclassify the entire stack. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Tesamorelin + Ipamorelin Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Tesamorelin + Ipamorelin Blend versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesamorelin%2011mg%20%2B%20Ipamorelin%206mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesamorelin%2011mg%20%2B%20Ipamorelin%206mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tesamorelin + Ipamorelin Blend",
    "subtitle": "Tesamorelin + Ipamorelin blend with component-aware tracking context.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [
      {
        "name": "Tesamorelin",
        "amount": "11mg"
      },
      {
        "name": "Ipamorelin",
        "amount": "6mg"
      }
    ],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Blend"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "coach",
    "useCases": [
      "Tesamorelin + Ipamorelin Blend is often approached as investigational support with variable evidence depth and variable product quality.",
      "Tesamorelin + Ipamorelin Blend is a blend, so interpretation should stay component-aware instead of treating every response as one signal.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tesamorelin + Ipamorelin Blend should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Tesamorelin + Ipamorelin Blend timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tesamorelin + Ipamorelin Blend often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tesofensine",
    "title": "Tesofensine",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tesofensine guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tesofensine discussions can drift into expectation-heavy narratives. This guide emphasizes appetite, sleep, and tolerability tracking with clean temporal context.",
    "dosingSection": {
      "overview": "For Tesofensine, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tesofensine and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Tesofensine users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Tesofensine timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tesofensine may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tesofensine appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesofensine: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesofensine",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesofensine: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesofensine",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesofensine: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tesofensine",
    "subtitle": "Tesofensine oral context with appetite and side-effect structure.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Tesofensine is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tesofensine should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Tesofensine timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tesofensine often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "test-base-no-ester",
    "title": "TEST BASE (NO Ester)",
    "aliases": [
      "TEST BASE (NO Ester)"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST BASE (NO Ester) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For TEST BASE, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TEST BASE should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST BASE and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TEST BASE outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST BASE timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST BASE may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST BASE appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST BASE (NO Ester): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20BASE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST BASE (NO Ester): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20BASE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST BASE (NO Ester): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST BASE",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "TEST BASE is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TEST BASE should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact TEST BASE timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TEST BASE often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "test-cypionate",
    "title": "TEST CYPIONATE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST CYPIONATE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST CYPIONATE should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For TEST CYPIONATE, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST CYPIONATE and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TEST CYPIONATE outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST CYPIONATE timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST CYPIONATE may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST CYPIONATE appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST CYPIONATE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20CYPIONATE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST CYPIONATE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20CYPIONATE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST CYPIONATE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST CYPIONATE",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "TEST CYPIONATE is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TEST CYPIONATE should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact TEST CYPIONATE timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TEST CYPIONATE often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "test-enanthate",
    "title": "TEST ENANTHATE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST ENANTHATE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST ENANTHATE belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For TEST ENANTHATE, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST ENANTHATE and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TEST ENANTHATE outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST ENANTHATE timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST ENANTHATE may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST ENANTHATE appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST ENANTHATE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20ENANTHATE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST ENANTHATE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20ENANTHATE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST ENANTHATE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST ENANTHATE",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "TEST ENANTHATE is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TEST ENANTHATE should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact TEST ENANTHATE timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TEST ENANTHATE often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "test-p",
    "title": "TEST P",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST P guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST P should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TEST P requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST P and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TEST P outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST P timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST P may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST P appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST P: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20P",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST P: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20P",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST P: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST P",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "TEST P is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TEST P should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact TEST P timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TEST P often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "test-suspension-100mg",
    "title": "TEST SUSPENSION 100mg",
    "aliases": [
      "TEST SUSPENSION 100mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST SUSPENSION 100mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST SUSPENSION belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TEST SUSPENSION requires conservative interpretation and explicit stop criteria before any protocol progression. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST SUSPENSION and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TEST SUSPENSION outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST SUSPENSION timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST SUSPENSION may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST SUSPENSION appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST SUSPENSION 100mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20SUSPENSION%20100mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST SUSPENSION 100mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20SUSPENSION%20100mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST SUSPENSION 100mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST SUSPENSION",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "TEST SUSPENSION is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TEST SUSPENSION should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact TEST SUSPENSION timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TEST SUSPENSION often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "test-undecanoate-300",
    "title": "TEST Undecanoate 300",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST Undecanoate 300 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For TEST Undecanoate 300, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TEST Undecanoate 300 should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TEST Undecanoate 300 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TEST Undecanoate 300 outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TEST Undecanoate 300 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TEST Undecanoate 300 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST Undecanoate 300 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST Undecanoate 300: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20Undecanoate%20300",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST Undecanoate 300: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20Undecanoate%20300",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST Undecanoate 300: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TEST Undecanoate 300",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "TEST Undecanoate 300 is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TEST Undecanoate 300 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact TEST Undecanoate 300 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TEST Undecanoate 300 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "testo-600mg",
    "title": "Testo 600mg",
    "aliases": [
      "Testo 600mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Testo 600mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Testo, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Testo should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Testo and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Testo outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact Testo timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Testo may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Testo appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Testo 600mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Testo%20600mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Testo 600mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Testo%20600mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Testo 600mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Testo",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Testo is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Testo should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Testo timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Testo often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "thymosin-alpha-1",
    "title": "Thymosin Alpha-1",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Thymosin Alpha-1 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Thymosin Alpha-1 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Thymosin Alpha-1, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Thymosin Alpha-1 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Thymosin Alpha-1 is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Thymosin Alpha-1 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Thymosin Alpha-1 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Thymosin Alpha-1 versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Thymosin Alpha-1: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Thymosin%20Alpha-1",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Thymosin Alpha-1: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Thymosin%20Alpha-1",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Thymosin Alpha-1: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Thymosin Alpha-1",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Thymosin Alpha-1 is often approached as investigational support with variable evidence depth and variable product quality.",
      "Thymosin Alpha-1 is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Thymosin Alpha-1 should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Thymosin Alpha-1 timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Thymosin Alpha-1 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "thymulin",
    "title": "Thymulin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Thymulin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Thymulin should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "Thymulin should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Thymulin and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Thymulin is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Thymulin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Thymulin may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Thymulin versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Thymulin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Thymulin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Thymulin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Thymulin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Thymulin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Thymulin",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Thymulin is often approached as investigational support with variable evidence depth and variable product quality.",
      "Thymulin is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Thymulin should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Thymulin timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Thymulin often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tirzepatide",
    "title": "Tirzepatide",
    "aliases": [
      "Mounjaro",
      "Zepbound"
    ],
    "category": "GIP/GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tirzepatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Tirzepatide has a bigger response range than most people expect. The difference between noise and clarity is how you log week-to-week appetite return, GI tolerance, and energy shifts around each escalation step.",
    "dosingSection": {
      "overview": "Tirzepatide should be reviewed over structured intervals, not single difficult days. [C1]",
      "protocolPatterns": [
        "Use fixed weekly checkpoints for Tirzepatide so appetite and GI trends stay comparable across titration steps. [C2]",
        "Avoid escalation decisions based on one difficult day; use full trend windows before protocol changes. [C3]"
      ],
      "monitoringWindows": [
        "Track nausea, satiety, bowel pattern, and hydration in relation to dose day and meal timing. [C2]",
        "Document escalation pauses and symptom recovery before any further dose progression. [C3]"
      ],
      "realWorldPatterns": [
        "Tirzepatide is often paced conservatively because response intensity varies significantly across individuals. [C4]",
        "Real-world teams commonly hold dose progression when GI burden clusters instead of pushing escalation timelines. [C1]",
        "Weekly appetite-return and bowel-pattern trend logs usually drive cleaner titration decisions than scale-only data. [C2]"
      ],
      "escalationBoundaries": [
        "Hold escalation if repeated vomiting, dehydration signs, or persistent inability to tolerate intake appears. [C1]",
        "Use product-specific missed-dose instructions rather than doubling a later dose to catch up. [C2]",
        "If side effects remain high across multiple weeks, reassess target dose and pace with your clinician. [C3]"
      ]
    },
    "trackingSignals": [
      "Track appetite return, meal size tolerance, and GI patterns around each Tirzepatide dose window.",
      "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
      "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely."
    ],
    "safetyFlags": [
      "Escalating GI symptoms, severe dehydration, or persistent intolerance should trigger rapid clinical review.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "How should Tirzepatide titration be paced based on my tolerance history and current goals?",
      "Which side effects should trigger immediate contact versus routine follow-up?",
      "What objective checkpoints should we use before increasing, holding, or decreasing dose?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tirzepatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Tirzepatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tirzepatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tirzepatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tirzepatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tirzepatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Tirzepatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tirzepatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Tirzepatide",
    "subtitle": "Dual GIP/GLP-1 weekly protocol with phase-aware response tracking.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "GLP-1/GIP",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Approved"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "clinical",
    "useCases": [
      "Tirzepatide is mainly discussed for glucose and/or weight-management goals under licensed clinical supervision.",
      "It is usually considered when lifestyle work alone is not giving stable metabolic outcomes.",
      "Tracking adherence, appetite curve, hydration, and GI tolerance is central to safe pacing."
    ],
    "candidateProfile": [
      "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
      "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
      "Users prepared for slow titration and occasional holds rather than forced escalation."
    ],
    "avoidanceFlags": [
      "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
      "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "serious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ]
    },
    "regulatoryContext": {
      "classification": "approved_label",
      "plainLanguageStatus": "Approved",
      "legalNotice": "Approved-label context may exist, but this page is educational only and not a dosing instruction."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tirzepatide response intensity varies significantly, so pacing should remain conservative and trend-driven.",
        "Escalation should follow tolerability recovery and documented symptom stability.",
        "Weekly pattern review usually outperforms single-day reactions for protocol decisions."
      ],
      "holdTriggers": [
        "Escalating intolerance, repeated poor oral intake, or worsening functional symptoms should prompt an immediate hold and clinical review.",
        "Any severe new symptom cluster after protocol changes should pause progression until evaluated."
      ],
      "resumeCriteria": [
        "Resume decisions are safer after symptoms stabilize and trend logs are reviewed with a licensed clinician.",
        "Progression should only continue when risk signals have eased and goals remain clinically appropriate."
      ],
      "trackingFocus": [
        "Track appetite return, meal size tolerance, and GI patterns around each Tirzepatide dose window.",
        "Log dose timing, hydration, and bowel pattern in a consistent format for week-to-week comparison.",
        "Document adherence breaks and restart effects so your clinician can adjust escalation pacing safely.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Adults with clinician-defined metabolic goals and a follow-up cadence that includes trend review.",
        "People willing to log weekly appetite return, bowel pattern, hydration, and adherence consistency.",
        "Users prepared for slow titration and occasional holds rather than forced escalation.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Active severe GI symptoms, persistent poor oral intake, or dehydration signs should pause escalation.",
        "Complex polypharmacy or unstable chronic disease raises interaction risk and needs tailored review.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Nausea, early satiety, reflux, constipation, or loose stool during adjustment windows.",
        "Temporary appetite suppression and reduced meal volume tolerance.",
        "Fatigue or low-energy days while hydration and intake patterns are still stabilizing."
      ],
      "sideEffectsSerious": [
        "Persistent vomiting, dehydration signs, or inability to maintain oral intake.",
        "Severe abdominal pain, escalating weakness, or unexpected symptom spikes after escalation.",
        "Allergic-type reactions such as facial swelling, breathing difficulty, or rapidly spreading rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tirzepatide often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tren-a",
    "title": "Tren A",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren A guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren A belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Tren A should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tren A and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Tren A outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tren A timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tren A may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren A appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren A: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20A",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren A: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20A",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren A: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tren A",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Tren A is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tren A should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Tren A timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tren A often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tren-base",
    "title": "Tren BASE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren BASE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren BASE belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Tren BASE should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tren BASE and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Tren BASE outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Tren BASE timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tren BASE may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren BASE appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren BASE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20BASE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren BASE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20BASE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren BASE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tren BASE",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Tren BASE is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tren BASE should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Tren BASE timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tren BASE often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tren-e",
    "title": "Tren E",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren E guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren E should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Tren E, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tren E and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Tren E outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Tren E timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tren E may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren E appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren E: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren E: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren E: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tren E",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Tren E is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tren E should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Tren E timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tren E often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tren-hex",
    "title": "Tren Hex",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren Hex guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren Hex should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "Tren Hex should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Tren Hex and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Tren Hex outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C2]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C3]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Tren Hex timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Tren Hex may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren Hex appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren Hex: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20Hex",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren Hex: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20Hex",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren Hex: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Tren Hex",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Tren Hex is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Tren Hex should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Tren Hex timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Tren Hex often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "trenmix-200mg",
    "title": "TRENMIX 200mg",
    "aliases": [
      "TRENMIX 200mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TRENMIX 200mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TRENMIX should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "TRENMIX should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TRENMIX and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TRENMIX outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C3]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C1]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact TRENMIX timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TRENMIX may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TRENMIX appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TRENMIX 200mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TRENMIX%20200mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TRENMIX 200mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TRENMIX%20200mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TRENMIX 200mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TRENMIX",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "TRENMIX is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TRENMIX should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact TRENMIX timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TRENMIX often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "tritren-225mg",
    "title": "TriTren 225mg",
    "aliases": [
      "TriTren 225mg"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TriTren 225mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TriTren should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For TriTren, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for TriTren and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "TriTren outcomes are usually easier to interpret when site rotation and administration timing are standardized. [C1]",
        "Many users log local reaction quality and onset/offset timing as the first safety signal layer. [C2]",
        "Conservative pacing with predefined review windows is commonly used before escalation. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact TriTren timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "TriTren may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TriTren appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TriTren 225mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TriTren%20225mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TriTren 225mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TriTren%20225mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TriTren 225mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "TriTren",
    "subtitle": "Reference guide for structured tracking and safer provider conversations.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "TriTren is generally used in protocols where injection timing and site quality materially affect outcomes.",
      "Benefit interpretation improves when symptom logs are tied directly to injection windows.",
      "A sterile technique checklist and site-rotation plan are core parts of safe use."
    ],
    "candidateProfile": [
      "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
      "Users with a defined objective and a clear review interval for benefit and tolerance.",
      "Patients ready to stop and reassess quickly if local or systemic reactions appear."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "serious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "TriTren should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact TriTren timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain sterile prep, site rotation, and date/time injection logs consistently.",
        "Users with a defined objective and a clear review interval for benefit and tolerance.",
        "Patients ready to stop and reassess quickly if local or systemic reactions appear.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site soreness, redness, or transient swelling.",
        "Headache, mild nausea, or short-term fatigue after administration windows.",
        "Short-lived appetite, sleep, or energy variability while adapting."
      ],
      "sideEffectsSerious": [
        "Spreading redness, fever, or progressive pain suggesting injection-site infection.",
        "Systemic reactions such as generalized rash, wheeze, or facial swelling.",
        "Persistent neurologic or cardiopulmonary symptoms after administration."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for TriTren often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "turinabol",
    "title": "Turinabol",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Turinabol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Turinabol belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Turinabol, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Turinabol and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Turinabol users do better when administration timing is anchored to a stable daily routine. [C2]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C3]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C1]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C3]",
        "Avoid catch-up dosing patterns after missed doses. [C1]",
        "Resume progression only after risk/benefit review with your provider. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact Turinabol timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Turinabol may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Turinabol appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Turinabol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Turinabol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Turinabol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Turinabol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Turinabol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Turinabol",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Turinabol is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Turinabol should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Turinabol timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Turinabol often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "vilon",
    "title": "Vilon",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Vilon guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Vilon belongs in a conservative conversation where uncertainty is documented, not glossed over. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "For Vilon, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Vilon and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Vilon is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log Vilon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "Vilon may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for Vilon versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vilon: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vilon",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vilon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vilon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vilon: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Vilon",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "Vilon is often approached as investigational support with variable evidence depth and variable product quality.",
      "Vilon is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Vilon should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log Vilon timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Vilon often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "vip",
    "title": "VIP",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "VIP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "VIP should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep cycle notes specific enough to compare across phases.",
    "dosingSection": {
      "overview": "VIP should only be discussed with strong risk framing and clinician-led decision checkpoints. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for VIP and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "VIP is usually paced conservatively in real-world use due to evidence and quality variability. [C2]",
        "Single-compound peptide protocols are usually reviewed against one primary endpoint at a time. [C3]",
        "Users with the cleanest outcomes tend to document exact timing, site quality, and symptom onset/offset windows. [C1]"
      ],
      "escalationBoundaries": [
        "Any severe or atypical systemic reaction should trigger immediate hold and medical review. [C3]",
        "Avoid escalating dose while simultaneously adding stacked compounds. [C1]",
        "If objective benefit is absent by the predefined review milestone, reassess continuation criteria. [C2]"
      ]
    },
    "trackingSignals": [
      "Log VIP timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
      "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
      "Use consistent checkpoints so subjective effects are anchored to repeatable observations."
    ],
    "safetyFlags": [
      "VIP may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "What is the clinical rationale for VIP versus better-established alternatives?",
      "Which biomarkers or symptom markers should define continuation versus discontinuation?",
      "How should stack complexity be reduced if signal quality is poor or adverse effects appear?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "VIP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=VIP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "VIP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=VIP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "VIP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "VIP",
    "subtitle": "Peptide guide focused on real-world tracking, risk framing, and clinician-ready notes.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Peptide",
        "Injectable Compound"
      ],
      "routeTags": [
        "Injectable"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": true
    },
    "voiceProfile": "caution",
    "useCases": [
      "VIP is often approached as investigational support with variable evidence depth and variable product quality.",
      "VIP is usually tracked as a single active signal so dose-response trends remain interpretable.",
      "Use is safest when there are pre-defined continuation and stop criteria before escalation."
    ],
    "candidateProfile": [
      "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
      "People who can define one primary endpoint and track it consistently before changing variables.",
      "Patients who can commit to stop rules if side effects rise or no objective signal emerges."
    ],
    "avoidanceFlags": [
      "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
      "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "serious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ]
    },
    "regulatoryContext": {
      "classification": "unregulated_market",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Unregulated-market compounds may lack standardized oversight; this page is educational only and not a usage directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "VIP should be interpreted conservatively because evidence quality and product consistency can vary.",
        "Avoid changing multiple compounds in the same review window so signal quality is preserved.",
        "Use pre-defined continuation and stop criteria before considering protocol progression."
      ],
      "holdTriggers": [
        "Unexpected systemic symptoms or rapidly worsening local reactions should trigger immediate hold and urgent clinical review.",
        "Any unclear adverse pattern in a stacked protocol should pause progression until attribution is clarified."
      ],
      "resumeCriteria": [
        "Resume only after clinical review confirms symptoms have stabilized and risk has been reassessed.",
        "Restart decisions should favor simpler protocols with clearer monitoring windows."
      ],
      "trackingFocus": [
        "Log VIP timing with target-domain notes such as recovery, tissue response, sleep, or mood changes.",
        "Mark stack composition clearly whenever additional compounds are used in the same cycle.",
        "Use consistent checkpoints so subjective effects are anchored to repeatable observations.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "Users with specialist oversight who understand evidence uncertainty and product-quality variability.",
        "People who can define one primary endpoint and track it consistently before changing variables.",
        "Patients who can commit to stop rules if side effects rise or no objective signal emerges.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Unknown source quality or poor storage/handling substantially increases avoidable risk.",
        "Do not combine multiple investigational compounds unless each signal can be tracked separately.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Injection-site irritation, transient headache, or short-term fatigue.",
        "Sleep, appetite, or mood shifts that can be hard to interpret in stacked protocols.",
        "Variable perceived response because product quality and handling may differ by source."
      ],
      "sideEffectsSerious": [
        "Progressive local reaction, fever, or severe pain at injection area.",
        "Unexpected neurologic, cardiovascular, or systemic symptoms after dosing windows.",
        "Any severe hypersensitivity-type reaction requiring urgent assessment."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "insufficient",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "insufficient",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "insufficient",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "insufficient",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for VIP often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "vitamin-d3",
    "title": "Vitamin D3",
    "aliases": [
      "Cholecalciferol"
    ],
    "category": "Vitamin",
    "status": "nutrient",
    "statusLabel": "Nutrient Support",
    "metaDescription": "Vitamin D3 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "Vitamin D3 looks simple, but good decisions are lab-driven. This guide favors measured recheck intervals over long blind supplementation runs.",
    "dosingSection": {
      "overview": "Vitamin D3 should follow a steady cadence with periodic tolerance and response review. [C1]",
      "protocolPatterns": [
        "Keep Vitamin D3 schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Vitamin D3, real-world dosing usually works best when baseline status is measured before aggressive correction. [C3]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C4]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C4]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Vitamin D3 timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Vitamin D3, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vitamin D3: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Vitamin%20D3&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vitamin D3: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vitamin%20D3",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vitamin D3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vitamin%20D3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Vitamin D3: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vitamin%20D3+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Vitamin D3",
    "subtitle": "Vitamin D3 guide with lab-first supplementation strategy.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Vitamin",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Vitamin D3 is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Nutrient Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Vitamin D3 should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Vitamin D3 timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "moderate",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Vitamin D3 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "winstrol-stanozolol",
    "title": "Winstrol(Stanozolol )",
    "aliases": [
      "Winstrol(Stanozolol )"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Winstrol(Stanozolol ) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "For Winstrol, risk control comes from explicit stop criteria and disciplined adverse-effect logging. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For Winstrol, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for Winstrol and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most Winstrol users do better when administration timing is anchored to a stable daily routine. [C3]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C1]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C2]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C1]",
        "Avoid catch-up dosing patterns after missed doses. [C2]",
        "Resume progression only after risk/benefit review with your provider. [C3]"
      ]
    },
    "trackingSignals": [
      "Document exact Winstrol timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "Winstrol may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Winstrol appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Winstrol(Stanozolol ): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Winstrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Winstrol(Stanozolol ): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Winstrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Winstrol(Stanozolol ): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "Winstrol",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "Winstrol is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Winstrol should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact Winstrol timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Winstrol often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "yk11",
    "title": "YK11",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "YK11 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "YK11 should be treated as high-uncertainty: cautious expectations, source-backed decisions, and early escalation of concerns. Use this page to keep protocol conversations clear, conservative, and evidence-aware.",
    "dosingSection": {
      "overview": "For YK11, uncertainty should lead to tighter monitoring, not faster escalation. [C1]",
      "protocolPatterns": [
        "Set one protocol objective for YK11 and avoid changing multiple variables in the same week. [C2]",
        "Write down the reason for every adjustment so retrospective reviews are evidence-based, not memory-based. [C3]"
      ],
      "monitoringWindows": [
        "Track symptom onset, peak, and resolution timing to improve safety signal quality. [C2]",
        "Escalate persistent or severe adverse effects early and document any intervention timing clearly. [C3]"
      ],
      "realWorldPatterns": [
        "Most YK11 users do better when administration timing is anchored to a stable daily routine. [C1]",
        "Meal context and co-medication timing are commonly tracked because they strongly influence tolerance. [C2]",
        "Dose adjustments are usually safer when based on multi-day patterns instead of single outlier days. [C3]"
      ],
      "escalationBoundaries": [
        "Pause escalation when adverse effects cluster or intensify after adjustments. [C2]",
        "Avoid catch-up dosing patterns after missed doses. [C3]",
        "Resume progression only after risk/benefit review with your provider. [C1]"
      ]
    },
    "trackingSignals": [
      "Document exact YK11 timing and whether it was used solo or as part of a broader stack.",
      "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
      "Log side effects by onset and resolution to improve follow-up decisions."
    ],
    "safetyFlags": [
      "YK11 may have incomplete long-term safety evidence; keep expectations conservative.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is YK11 appropriate for my goals and risk profile compared with established options?",
      "Which baseline and follow-up checks should be tracked, and at what cadence?",
      "What adverse-effect thresholds should trigger urgent contact?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "YK11: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=YK11",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "YK11: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=YK11",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "YK11: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0",
    "displayTitle": "YK11",
    "subtitle": "Oral compound guide for adherence quality, side-effect timing, and escalation decisions.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Oral Compound"
      ],
      "routeTags": [
        "Oral"
      ],
      "statusTags": [
        "Experimental"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "caution",
    "useCases": [
      "YK11 is usually used for symptom- or condition-focused goals where oral adherence is practical.",
      "Meal timing, sleep, and co-medication context often determine whether tolerance stays stable.",
      "Progress is cleaner when one protocol variable is changed at a time."
    ],
    "candidateProfile": [
      "People who can maintain consistent daily timing and document meal/medication context.",
      "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
      "Patients who can avoid self-directed escalation when short-term results fluctuate."
    ],
    "avoidanceFlags": [
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "serious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ]
    },
    "regulatoryContext": {
      "classification": "investigational",
      "plainLanguageStatus": "Experimental",
      "legalNotice": "Investigational context means uncertainty remains high; this page is educational only and not a dosing directive."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "YK11 should be paced conservatively with one protocol variable reviewed at a time.",
        "Trend quality improves when logs are captured consistently across comparable windows.",
        "Escalation decisions should be anchored to objective review rather than day-to-day variability."
      ],
      "holdTriggers": [
        "Rapidly worsening side effects or new severe symptoms should trigger immediate hold and clinician review.",
        "If risk signals rise faster than benefit signals, pause progression and reassess."
      ],
      "resumeCriteria": [
        "Resume after stability returns and a clinician confirms the risk-benefit balance remains acceptable.",
        "Continue with conservative pacing and explicit monitoring checkpoints."
      ],
      "trackingFocus": [
        "Document exact YK11 timing and whether it was used solo or as part of a broader stack.",
        "Track target outcomes with date-stamped notes and at least one objective marker where possible.",
        "Log side effects by onset and resolution to improve follow-up decisions.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence confidence is limited, so this section should be treated as educational context rather than dosing instruction."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People who can maintain consistent daily timing and document meal/medication context.",
        "Users with a specific symptom or lab objective and objective follow-up checkpoints.",
        "Patients who can avoid self-directed escalation when short-term results fluctuate.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "Stomach discomfort, bowel-pattern changes, or appetite variability.",
        "Headache, mild dizziness, or transient sleep disturbance.",
        "Tolerance swings linked to meal timing or co-medication timing."
      ],
      "sideEffectsSerious": [
        "Escalating abdominal pain, persistent vomiting, or severe dehydration signs.",
        "Confusion, severe weakness, or rapid deterioration after dose changes.",
        "Allergic reactions with breathing, swelling, or widespread rash."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "low",
      "overallRationale": "Confidence is limited due to variability in source quality, population fit, or regulatory standardization.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "low",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "low",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "low",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "low",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "low",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "low",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "low",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "No broadly standardized regulated dosing protocol is available for many real-world contexts.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for YK11 often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  },
  {
    "slug": "zinc",
    "title": "Zinc",
    "aliases": [
      "Zn"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Zinc guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Zinc tracking is most useful when you link dose timing, tolerance, and symptom context in one log entry. Use this page to connect symptom notes to lab timing and supplementation cadence.",
    "dosingSection": {
      "overview": "For Zinc, conservative adjustments and measured rechecks are safer than abrupt protocol jumps. [C1]",
      "protocolPatterns": [
        "Keep Zinc schedule consistent and tie changes to objective follow-up markers when available. [C2]",
        "Avoid aggressive jumps in intake without clinician guidance, especially when overlapping other supplements. [C3]"
      ],
      "monitoringWindows": [
        "Log dose timing, meals, and symptom context so tolerance patterns are interpretable. [C2]",
        "Recheck labs on a planned cadence and document how values map to symptom changes. [C3]"
      ],
      "realWorldPatterns": [
        "For Zinc, real-world dosing usually works best when baseline status is measured before aggressive correction. [C2]",
        "Practitioners often reassess labs or symptom markers before moving from correction to maintenance. [C3]",
        "Stack simplification (one variable change at a time) is commonly used to avoid attribution errors. [C1]"
      ],
      "escalationBoundaries": [
        "Pause aggressive correction when side effects rise faster than objective benefit markers. [C3]",
        "Do not layer overlapping nutrient products without reconciling total intake and review windows. [C1]",
        "Re-check objective markers before extending high-intensity phases. [C2]"
      ]
    },
    "trackingSignals": [
      "Track Zinc timing, meal context, and any tolerance issues in the same daily format.",
      "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
      "Note changes in other supplements or medications that could confound trend interpretation."
    ],
    "safetyFlags": [
      "Excess supplementation can create unintended toxicity or interactions; avoid unsupervised high-dose changes.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Do my current labs support using Zinc, and what target range should we monitor?",
      "What dosing ceiling should I avoid without additional testing?",
      "How should this fit with my current medications and supplement stack?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Zinc: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Zinc: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Zinc",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Zinc: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Zinc+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0",
    "displayTitle": "Zinc",
    "subtitle": "Micronutrient guide with lab-aware context and conservative safety boundaries.",
    "acronymInfo": {
      "code": null,
      "meaning": null,
      "isVendorDefined": false,
      "note": null
    },
    "composition": [],
    "taxonomy": {
      "classTags": [
        "Mineral",
        "Supportive"
      ],
      "routeTags": [
        "Mixed/Unknown"
      ],
      "statusTags": [
        "Support/Nutrient"
      ],
      "formatTags": [
        "Single Compound"
      ],
      "isPeptideLike": false
    },
    "voiceProfile": "support",
    "useCases": [
      "Zinc is generally used to correct or prevent a confirmed nutrient gap, not as open-ended high-dose therapy.",
      "Best decisions come from lab context, symptom context, and a defined re-check window.",
      "Use should be goal-oriented, with clear criteria for tapering, maintenance, or stop."
    ],
    "candidateProfile": [
      "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
      "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
      "Patients whose medication list has been reviewed for interaction or absorption conflicts."
    ],
    "avoidanceFlags": [
      "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
      "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
      "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
      "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
      "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review."
    ],
    "sideEffects": {
      "common": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "serious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ]
    },
    "regulatoryContext": {
      "classification": "nutrient_support",
      "plainLanguageStatus": "Mineral Support",
      "legalNotice": "Nutrient context should be personalized to labs and clinical history; this page is educational only."
    },
    "dosingFramework": {
      "pacePrinciples": [
        "Zinc should be framed as targeted support with objective re-check windows, not open-ended escalation.",
        "Adjustment pace should follow symptom and laboratory context reviewed by a qualified clinician.",
        "Stack complexity should stay low so changes remain interpretable."
      ],
      "holdTriggers": [
        "Worsening intolerance or imbalance symptoms should pause progression pending medical review.",
        "Any severe new symptom pattern during a support phase should trigger prompt clinical evaluation."
      ],
      "resumeCriteria": [
        "Resume only after symptom stabilization and updated clinical context confirm benefit-to-risk remains acceptable.",
        "Continue with conservative pacing and clear stop criteria discussed with your clinician."
      ],
      "trackingFocus": [
        "Track Zinc timing, meal context, and any tolerance issues in the same daily format.",
        "Record relevant labs and symptoms side by side so supplementation effects are easier to interpret.",
        "Note changes in other supplements or medications that could confound trend interpretation.",
        "Capture symptom timing relative to protocol windows so trend review stays objective.",
        "Document holds, restarts, and clinically significant events in the same structured format."
      ],
      "uncertaintyStatement": "Evidence quality is moderate and still requires individualized clinical interpretation for safe decision-making."
    },
    "riskScreen": {
      "whoMayDiscussWithProvider": [
        "People with confirmed deficiency risk, low intake, or objective clinical reason for targeted support.",
        "Users who can re-check labs/symptoms on schedule instead of extending high doses indefinitely.",
        "Patients whose medication list has been reviewed for interaction or absorption conflicts.",
        "People who can review risks, interactions, and goals with a licensed clinician before protocol changes."
      ],
      "whoShouldAvoidOrPause": [
        "Renal impairment, absorption disorders, or known mineral balance disorders need individualized dosing plans.",
        "Stacking multiple products with overlapping micronutrients can raise toxicity risk unexpectedly.",
        "Pregnancy, breastfeeding, and active conception planning should be reviewed with a specialist before use.",
        "Prior severe hypersensitivity reaction to related compounds is a strong caution signal.",
        "Rapidly worsening symptoms after dose changes should trigger immediate hold and clinical review.",
        "Anyone with severe new symptoms should pause and seek urgent medical review."
      ],
      "sideEffectsCommon": [
        "GI upset, stool changes, or nausea when timing/formulation does not fit tolerance.",
        "Mild headache or taste changes depending on formulation and co-supplement stack.",
        "Variable symptom response when baseline deficiency status is unclear."
      ],
      "sideEffectsSerious": [
        "Signs of over-correction or imbalance when high doses are continued without re-checks.",
        "Worsening neurologic, cardiac, or severe GI symptoms after dose increases.",
        "Allergic-type reactions, including swelling, rash progression, or breathing symptoms."
      ],
      "emergencySignals": [
        "Trouble breathing, facial swelling, chest pain, severe neurologic symptoms, or fainting requires emergency care.",
        "Persistent inability to keep fluids down with worsening weakness requires urgent evaluation.",
        "Any severe rapid-onset reaction after use should be treated as an emergency signal."
      ]
    },
    "evidenceProfile": {
      "overall": "moderate",
      "overallRationale": "Confidence is moderate based on authoritative sources, but personalization and clinical review are still required.",
      "bySection": [
        {
          "sectionKey": "use_cases",
          "confidence": "moderate",
          "rationale": "Use-case framing is based on source summaries and clinical context.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "risk_screen",
          "confidence": "moderate",
          "rationale": "Risk framing prioritizes safety signals and conservative escalation language.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_framework",
          "confidence": "moderate",
          "rationale": "Framework focuses on non-prescriptive pacing and hold/resume boundaries.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_pace",
          "confidence": "moderate",
          "rationale": "Pace principles are trend-based and avoid numerical protocol instructions.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_hold",
          "confidence": "moderate",
          "rationale": "Hold triggers emphasize early escalation of concerning symptoms.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_resume",
          "confidence": "moderate",
          "rationale": "Resume criteria require stability and clinician review before progression.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "dosing_tracking",
          "confidence": "moderate",
          "rationale": "Tracking focus is designed for structured clinical discussions and safer trend interpretation.",
          "citationIds": [
            "C1",
            "C2"
          ]
        },
        {
          "sectionKey": "community_reports",
          "confidence": "low",
          "rationale": "Community summaries are observational and non-standardized by design.",
          "citationIds": [
            "C1"
          ]
        },
        {
          "sectionKey": "sources",
          "confidence": "low",
          "rationale": "Source confidence depends on the quality and breadth of cited references.",
          "citationIds": [
            "C1",
            "C2"
          ]
        }
      ],
      "dataGaps": [
        "No universal protocol fits every risk profile, comorbidity pattern, or co-medication context.",
        "Most evidence still requires individualized interpretation and clinician review for safe application.",
        "Long-term comparative data may be limited for specific populations and combination protocols."
      ]
    },
    "communityReports": {
      "included": true,
      "confidence": "low",
      "summary": [
        "Community logs for Zinc often emphasize pacing decisions around tolerability trends rather than rapid progression.",
        "Reports frequently describe better signal quality when one protocol variable is changed per review window.",
        "Community observations vary widely and may be influenced by source quality, expectation effects, and incomplete tracking."
      ],
      "safetyCaution": "Community summaries are low-confidence observations and should never replace individualized medical guidance.",
      "sourcePolicy": "summarized_nonlinked"
    }
  }
]
